

2010

Until there is a cure...



INTERNATIONAL
MYELOMA
FOUNDATION

2010 ANNUAL REPORT

...There is the IMF

INTERNATIONAL MYELOMA FOUNDATION




*Dedicated to improving
the quality of life of myeloma patients
while working toward prevention and a cure.*



EDUCATION



RESEARCH



SUPPORT



ADVOCACY

2010 ANNUAL REPORT

TABLE OF CONTENTS

<i>Letter from the Chairman</i>	2
<i>Update from the President</i>	3
<i>Education</i>	4
<i>Research</i>	7
<i>Support</i>	14
<i>Advocacy</i>	16
<i>Development</i>	18
<i>Financial Statement</i>	23
<i>Honor Roll</i>	26





Brian G.M. Durie, MD, Chairman

Medical Director, Aptium Oncology Myeloma Consortium, Aptium Oncology, Inc.
Specialist in Multiple Myeloma and Related Disorders,
Cedars-Sinai Outpatient Cancer Center
Los Angeles, CA, USA

IMF Board of Directors

Brian G.M. Durie, MD
Chairman of the Board
Los Angeles, CA

Thomas Bay, PhD
Founder, Tom Bay Speaks Up, Inc.
Los Alamitos, CA

Lorraine Alterman Boyle
Journalist
New York, NY

Mark S. Di Cidila
Account Manager, Epicor Software Corporation
Orange, CA

Donna Feig
Vice President, Foreign Parts Distributors
Miami Beach, FL

Michael S. Katz, MBA
Senior Vice President, Booz & Company
Bayside, NY

Benson Klein, JD
Principal Member, Ward & Klein
Bethesda, MD

Robert A. Kyle, MD
Professor of Medicine and Laboratory Medicine,
Mayo Clinic
Rochester, MN

Edith P. Mitchell, MD
Clinical Professor of Medicine,
Thomas Jefferson University
Brigadier General, National Guard
Philadelphia, PA

Charles Newman, MS
Founder, CEO & President, ReCellular, Inc.
Principal, Newman Computer Group
Ann Arbor, MI

Susie Novis
President, International Myeloma Foundation
Los Angeles, CA

John O'Dwyer
Retired Executive
Plano, TX

S. Vincent Rajkumar, MD
Professor of Medicine,
Mayo Clinic
Rochester, MN

Matthew Robinson, MBA
Vice President, Sales and Business Development
Warner Bros. International Television
Los Angeles, CA

E. Michael D. Scott, CPA, JD
Proprietor & Executive Vice President, Vox Media
Newtown, PA

Igor Sill
Co-Founder & Managing Director,
Geneva Venture Partners
Founder & Chairman,
Geneva Group International
San Francisco, CA

Allan Weinstein, PhD
Director, St. Francis Medical Technologies, Inc.
Phoenix, AZ

Amy Weiss
Executive Vice President, Business Affairs
Brillstein Entertainment Partners
Beverly Hills, CA

Dear Supporters of the International Myeloma Foundation,

It has now been 20 years since the International Myeloma Foundation forged its commitment to helping myeloma patients and their families all around the world.

The IMF is now 195,000 members strong and active in 113 countries. It is an honor to be part of such a passionate community. I believe the work done by the IMF over the past 20 years has helped in the ongoing transition of myeloma from “deadly” to “treatable.” I also firmly believe that the IMF will play an equally important role in transitioning the disease from “treatable” to “preventable.” Although it hasn’t happened yet, prevention *will* happen as we continue to build upon the successes described in these pages – the IMF’s work from October 2009 through September 2010.

In June 2010, the IMF held the Inaugural International Myeloma Working Group Summit. This summit was a true workshop, bringing together the world’s foremost myeloma leaders to think through and discuss all the issues on the research horizon. While together in June, we established unprecedented consensus agreements and began shaping the direction of future research collaborations, all in order to achieve the most promising results for myeloma patients in the shortest period of time possible.

The IMF also remains dedicated to effective and directed research through Bank On A Cure®, which continues to reach exciting milestones through our significant data analysis in partnership with other important research entities, including the National Cancer Institute. This analysis provides us with important building blocks that will lead us to the day where myeloma will truly be treatable as a chronic disease.

Just as importantly, the IMF remains dedicated to sharing scientific progress directly with patients, families, friends, caregivers, and healthcare professionals all around the world. New technology empowers us, and the IMF embraces all of the information portals at our disposal. We will continue to use every platform available to inform patients and doctors about effective treatment choices, to support our families, and to advocate on behalf of the global myeloma community.

Twenty years is the mark of a long journey. Yes, it has sometimes been frustrating, but far more often it has been incredibly successful and profoundly gratifying. This is because of you – our supporters, our partners, and our collaborators. Here’s to many more successful and gratifying achievements as we continue forward.

Sincerely yours,

Brian G.M. Durie, MD
Chairman, IMF Board of Directors

Susie Novis, President
International Myeloma Foundation



Dear IMF Supporter,

As I sat in front of the blank screen of my laptop to write this update, I found myself hard pressed to know what to say. *So much* is being accomplished by *so many people* every single day.

Then I said to myself, "Let's just make a list and see what happens." Here it is:

- Despite the continuing recession, the IMF again received high levels of support from individual donors, events organized by our members, corporate donors, and one specific miracle.
- Michael McKean, playing in memory of his friend Lee Grayson, won the nationally televised 2010 *Jeopardy!* Million Dollar Celebrity Invitational. The \$1,000,000 payout was the largest single gift the IMF has received to date and established the McKean/Grayson Research and Education Fund.
- At the Inaugural Summit of the International Myeloma Working Group in Barcelona, Spain, nearly 70 of the world's leading experts came together to chart the future of myeloma treatment and care.
- IMF advocacy helped to ensure passage of legislation in Connecticut mandating coverage of oral anti-cancer drugs at comparable rates to that of intravenous infusions and other procedures.
- We began to make high-quality information and care available for myeloma patients in the world's most populous nation through the launch of a partnership between the IMF and a cooperative agreement with the Chinese Health Promotion Foundation.
- The annual meeting of the American Society of Hematology in December was awash with exciting and important new data about the use of approved and investigational treatments for every stage of myeloma.
- Our Annual Comedy Celebration in Los Angeles – hosted again by Ray Romano – packed 1,200 people into the Wilshire Ebell Theatre for a stellar evening of entertainment.

There are so many people to thank for their roles in everything we accomplished together in the fiscal year reported here. Time and space won't allow me to list them all. I must, however, thank Michael McKean for his astonishing gift – and his graciousness in the face of all the publicity. I need to thank two IMF Board members, Loraine Boyle and Amy Weiss, for making the Annual Comedy Celebration such an outstanding success. And I really must try to thank everyone else: all our corporate and pharmaceutical partners; the IMF's astonishing and indefatigable staff; every member of the IMF from around the world who found a way to continue supporting us; all the physicians, scientists, and other healthcare professionals who work with us because of their passion to improve opportunities for myeloma patients; and lastly Michael Katz – another member of the IMF Board – for his determination to make the IMF's website the best source of myeloma information absolutely anywhere.

Without all these people and so many more, none of the accomplishments listed in these pages would have been possible. We are so grateful to you all for your continued support.

With gratitude,

A handwritten signature in blue ink that reads "Susie Novis".

Susie Novis
IMF President

IMF Staff

Susie Novis
President

David Girard
Executive Director

Jennifer Scarme
Chief Financial Officer

Daniel Navid
Senior Global Analyst

Diane Moran
Senior Vice President, Strategic Planning

Heather Cooper Ortner
Vice President, Development

Lisa Paik
Vice President, Clinical Education & Research Initiatives

Betty Arevalo
Database & Inventory Control

Arin Assero
Director of Advocacy

Alci Avelar
Inventory Control Associate

Suzanne Battaglia
Director of Member Events

Nancy Baxter
Hotline Coordinator

Zsolt Bayor
IT Consultant

Debbie Birns
Hotline Coordinator

Joanie Borbely
Regional Co-Director of Support Groups, SE

Greg Brozeit
European Programs

Meghan Buzby
Advocacy Grassroots Liaison

Kelly Cox
Director, Support Groups Outreach

Paul Hewitt
Hotline Coordinator

Spencer Howard
Meeting & Event Services

Marya Kazakova
Publications Editor

Melissa Klepetar
Hotline Associate

Phil Lange
Accountant

Andy Lebkuecher
Regional Co-Director, Support Groups SE

Kemo Lee
Specialty Member Services Coordinator

Randi Lovett
Director of Annual Giving & Social Media

Kerri Lowe
Development Intern

Jim Needham
Publication Design

Selma Plascencia
Data Specialist, Office Manager

Abbie Rich
Webmaster

Robin Tuohy
Regional Director, Support Groups NE

Judy Webb
Project Manager



Nick Menedis
Reynoldsburg, OH

When Nick Menedis was diagnosed with myeloma in August 2006, he quickly willed himself into an empowering frame of mind. “Rather than *Why me?* I figured *Why not me?*” Nick says. He knew much younger people fighting cancer including his own daughter, who had recently been diagnosed with breast cancer when she was six months pregnant.

Nick used his daughter’s success as inspiration for perseverance. He was determined to see his grandchildren graduate from high school.

He also feels lucky that he quickly found the IMF. “Too many people start by looking up ‘myeloma’ and seeing ‘there is no cure.’ Because of the IMF, I started with a message of hope,” Nick says.

Nick took notice of the IMF’s Patient & Family Seminars through the website (myeloma.org) and then read more about them in *Myeloma Today*. He first attended one in 2007. “I was amazed,” Nick recalls. “I learned so much from the presenters and talking with other patients. It was incredibly encouraging.” He was also thrilled to have one-on-one access to leading myeloma professionals dedicated to spending time with anyone in need.

“I’m still learning,” Nick says. Now he feels an even greater responsibility to learn, because he and his wife, Sandy, have partnered with the IMF in starting a new myeloma support group. This past year Nick attended the Cincinnati Patient & Family Seminar, as well as an IMF Regional Community Workshop held there. He is grateful for the additional knowledge he gained and relationships he built through these experiences.

“The focus of our support group is teaching patients to take control of their treatment and to work with their doctors,” Nick says. “I pray for a cure, but I am confident that we are entering an era where myeloma will be treated as a chronic condition rather than an incurable disease.”

EDUCATION

“We lived on an emotional roller coaster, with much uncertainty and great apprehension. Then we found the IMF and gained the knowledge we needed to feel more in control of our lives.”

– JOANNE GUNTHER, Aberdeen, MD

Myeloma is one of the most prevalent forms of blood cancer, affecting more than 750,000 patients worldwide. Prior to diagnosis, most patients and their families have never heard of myeloma. But knowledge is power, and the IMF is committed to gathering a comprehensive array of information and sharing it with myeloma patients, families, caregivers, and healthcare professionals throughout the world.

The IMF is a primary resource for up-to-date disease and treatment information for new patients and families, as well as for long-term patients and families. The IMF also remains dedicated to serving as a valued educational asset for myeloma healthcare professionals. The knowledge provided means that patients and their caregivers can join healthcare providers in a decision-making partnership, creating the best possible quality of life for every myeloma patient.

IMF Patient & Family Seminars

“You will learn so much, it will help you get a perspective of the disease, and you will meet many others in your shoes. You will leave feeling much less afraid, much less alone, and empowered to go forward with confidence.”

– SUE GOFF ENRIGHT, Jackson, WI



The IMF’s flagship Patient & Family Seminars present vital information about new treatments, provide one-on-one time with myeloma specialists, and allow participants to share their experiences and gain strength from hearing other people’s stories. Premier myeloma experts volunteer their time to the IMF’s Patient & Family Seminars because the knowledge gained is vital, and empowers patients and their families to make intelligent treatment choices that are specifically right for them.

Since 1993, the IMF has hosted 145 Patient & Family Seminars in 14 countries all around the world. From

October 2009 to September 2010, more than 900 participants attended U.S.-based seminars in Cincinnati, OH; Los Angeles, CA; Philadelphia, PA; and Portland, OR. Internationally, 2,050 participants attended international seminars in Heidelberg, Germany; Madrid, Spain; Niigata City, Japan; Paris, France; Podebrady, Czech Republic; Rehovot, Israel; São Paulo, Brazil; and Turin, Italy.



IMF Regional Community Workshops

The IMF is dedicated to connecting with as many patients as possible through live and engaging opportunities. Therefore, in addition to its flagship Patient & Family Seminars, from October 2009 to September 2010, the IMF facilitated Regional Community Workshops in Cincinnati, OH; Denver, CO; Honolulu, HI; Las Vegas, NV; Longview, TX; Milwaukee, WI; Overland Park, KS; Salt Lake City, UT; Shreveport, LA; and Spokane, WA, attended by a total of 384 participants. The IMF also facilitated international Community Workshops in Berlin, Koblenz and Leipzig, Germany, and Florence, Italy, attended by a total of 360 participants.

Publications

“It is so helpful to know the results of current research and the general consensus of the Scientific Advisory Board of the IMF. It would take me forever to find all the information on my own.”

– KRIS GRANDINETTI, Peoria, AZ

The IMF produces comprehensive but “user-friendly” information for the entire myeloma community. The IMF’s publications library includes an extensive catalog of booklets, tip cards, articles, and DVDs, all written, created, and produced by the IMF with oversight by its Scientific Advisory Board. The IMF library’s broad scope includes information about myeloma treatment options, clinical trials, and quality of life considerations for patients and physicians. IMF publications are provided free of charge, in 16 languages.



The IMF remains at the forefront of assessing the latest and newest information and promptly and effectively disseminating it to the myeloma community. From October 2009 through September 2010, the IMF created nine new publications. Fifteen additional publications were updated with the latest information.

Many of these publications are bundled into the IMF InfoPack, designed to provide newly diagnosed patients and their families with a well-rounded understanding of the disease and patient care. From October 2009 to September 2010, the IMF provided approximately 25,000 InfoPacks to patients, healthcare providers, and support groups around the world.

The IMF’s quarterly newsletter *Myeloma Today* is the go-to resource for learning about the latest advances in myeloma treatment, research, and quality of life issues. A print subscriber base of nearly 13,724 (a three percent increase over the previous year), in addition to pass-along rates and web-views, meant an estimated additional *Myeloma Today* readership of more than 100,000 per issue from October 2009 through September 2010.

The *Myeloma Minute* is the IMF’s email newsletter, providing up-to-the-minute information about myeloma research, events, and IMF programs. In September 2010, its subscriber-base was 26,500 readers. *Myelom Merkur*, the newsletter’s German edition, increased its readership to 2,000. The French, Italian, and Spanish editions (*Le Messager de Myélome*, *Il Messaggero di Mieloma* and *Mensajero del Mieloma*) brought an additional 800 subscribers as of September 2010.

IMF 2010 List of Publications

*CITINGS: Freelite™/Hevylite™***

*CITINGS: Novel Therapies***

*Clinical Trial Data Sheets***

Concise Review of the Disease and Treatment Options

Guide to XIth International Myeloma Workshop – Washington DC 2009

*Highlights from ASCO 2010 – for Patients**

*Highlights from ASCO 2010 – for Physicians**

*Highlights from ASH 2009 – for Patients**

*Highlights from ASH 2009 – for Physicians**

I Have Myeloma... What’s Next? (DVD)

*IMF Patient and Family Seminar: Heidelberg 2009 (DVD)**

*IMF Patient and Family Seminar: Los Angeles 2010 (DVD)**

*IMF Patient and Family Seminar: Paris 2009 (DVD)**

*IMF Patient and Family Seminar: Torino 2009 (DVD)**

*IMF Patient Handbook***

International Staging System Tip Card

*Mozobil® Tip Card**

Multiple Myeloma Tip Card

Myeloma Manager™ Tip Card

*Myeloma Matrix: Clinical Trials***

*Myeloma Minute: e-newsletter***

*Myeloma Today***

*Understanding Anemia and Fatigue***

Understanding Balloon Kyphoplasty & Myeloma-Induced Vertebral Compression Fractures

*Understanding Bisphosphonate Therapy***

*Understanding Dexamethasone and other Steroids***

*Understanding Revlimid®***

*Understanding Serum Free Light Chain Assays***

*Understanding Stem Cell Transplant***

*Understanding Thalidomide Therapy***

*Understanding VELCADE® (bortezomib) for Injection Therapy***

*New for 10/1/09 - 9/30/10

**Updated for 10/1/09 - 9/30/10



Teresa Miceli, RN, BSN
Mayo Clinic Rochester
Rochester, MN

Teresa Miceli is proud that she has spent her entire career, since 1991, at the Mayo Clinic Rochester, working in the area of blood and marrow transplantation. Surrounded by leading myeloma physicians, she had always been familiar with the IMF. But she wasn't aware of the IMF's scope of programs and services until she joined its Nurse Leadership Board (NLB) as a founding member in 2006.

Now, as a regular presenter at Patient & Family Seminars and Regional Community Workshops, Teresa views these IMF programs as a true highlight of her work. "Meeting myeloma survivors from across the country is such an inspiration," she says. "I am so grateful for these opportunities to provide education to patients and caregivers regarding possible side effects and management of the therapies they are receiving."

Teresa's commitment to addressing myeloma's side effects includes leading the Bone Health & Bone Disease section of the NLB's ongoing Survivorship Care Plan. "The need to manage bone disease, pain, and related mobility issues is paramount in promoting quality of life," Teresa says. "We must recognize how bone disease impacts day-to-day living – for the long term."

Teresa has also served as chair of the myelo-suppression task force, part of the NLB's *Consensus Guidelines*, published in 2008, an experience that solidified her views of myeloma nursing. "Nurses play a key role in the education of patients and other healthcare providers," she says. It is this knowledge, she believes, that provides patients with hope.

"When I agreed to participate in the first NLB meeting, I had no idea what the vision was going to be," Teresa reflects. "Once we came together, the energy and synergy were amazing, and the rest is history – and the future!"


Nurse Leadership Board

“Our membership has become a very close network that represents the best nurses in the field of myeloma.”

– JOSEPH D. TARIMAN, RN, MN, PHD(C), ARNP-BC, OCN
Northwestern Myeloma Program, Chicago, IL

The IMF Nurse Leadership Board (NLB) consists of 20 myeloma nurse experts from major treatment centers throughout the U.S. The NLB provides a forum for addressing the needs of the myeloma nursing and patient communities.

In October 2009, the NLB convened its fifth organization-wide meeting, in New York City, with a focus on advancing a series of publications for their *Long Term Survivorship Care Plan* for myeloma patients. At this meeting they presented the rationale, content, and a top line overview of the manuscripts in development: renal complications, functional mobility and safety, bone health and bone disease, sexuality and sexual dysfunction, and health maintenance. The NLB also identified future projects, including Consensus Guidelines in Transplantation (to include education, the decision-making process, timing, drugs, and stem-cell collection issues) and developing a health maintenance online interactive tool that can be integrated with the IMF's Myeloma Manager™.



In May 2010, the NLB presented a summary of the five core elements of their *Long Term Survivorship Care Plan* at the Oncology Nursing Society annual meeting. The NLB presented to a full-capacity room of 625 nurses.

From October 2009 through September 2010, NLB members also spoke at IMF Patient & Family Seminars and Regional Community Workshops, facilitated informational conference calls with IMF support groups, and continued its NLB Speaker Programs – educating community nurses about myeloma treatment side effects.

IMF Nurse Leadership Board Members

Page Bertolotti, RN, BSN, OCN
Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA

Elizabeth Bilotti, RN, MSN, APRN, BC
The John Theurer Cancer Center at HUMC
Multiple Myeloma Division
Hackensack, NJ

Kathleen Colson, RN, BSN, BS
Dana-Farber Cancer Institute
Boston, MA

Deborah Doss, RN, OCN
Dana-Farber Cancer Institute
Boston, MA

Beth Faiman, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, OH

Charise Gleason, MSN, NP-BC, AOCNP
Emory University Winship Cancer Institute
Atlanta, GA

Bonnie Jenkins, RN
University of Arkansas Medical School
Little Rock, AR

Kathy Lilleby, RN
Fred Hutchinson Cancer Research Center
Seattle, WA

Patricia A. Mangan, APRN, BC
Abramson Cancer Center
at the University of Pennsylvania
Philadelphia, PA

Emily McCullagh, RN, NP-C, OCN
Memorial Sloan-Kettering Cancer Center
New York, NY

Ann McNeill, RN, MSN, APN
The John Theurer Cancer Center at HUMC
Multiple Myeloma Division
Hackensack, NJ

Teresa Miceli, RN, BSN
Mayo Clinic – Rochester
Rochester, MN

Kena C. Miller, RN, MSN, FNP
Roswell Park Cancer Institute
Buffalo, NY

Tiffany Richards, MS, ANP, AOCNP
MD Anderson Cancer Center
Houston, TX

Sandra Rome, RN, MN, AOCN
Cedars-Sinai Medical Center
Los Angeles, CA

Jacy Spong, RN, BSN, OCN
Mayo Clinic – Arizona
Scottsdale, AZ

Joseph Tariman, PhD, MN, APRN, BC
Northwestern University
Chicago, IL

NLB Associate Members

B. Nadine Baxter-Hale, MN, MS, APRN-BC, AOCNP
University of Arkansas for Medical Sciences
Myeloma Institute of Research and Therapy
Little Rock, AR

Elizabeth Finley-Oliver, RN
H. Lee Moffitt Cancer Center
and Research Institute
Tampa, FL

Sandra Kurtin, RN, MS, AOCN, ANP-C
Arizona Cancer Center
Tucson, AZ

Kimberly Noonan, RN, ANP, AOCN
Dana-Farber Cancer Institute
Boston, MA

RESEARCH

The IMF is a leader of innovative, globally collaborative myeloma research as a means of improving quality of life while working toward prevention and a cure. The IMF is at the forefront as the myeloma community enters the era of “tailored treatment” – with new therapies and approaches aimed at customizing each patient’s specific needs. This will lead to an era where myeloma will be managed as a chronic disease rather than a terminal diagnosis.

International Myeloma Working Group

“The International Myeloma Working Group plays a big role in the delivery of high-quality, up-to-date treatment for myeloma patients worldwide by developing and publishing important practice guidelines and carrying out key research projects that have a direct impact on the diagnosis, prognosis, and treatment of myeloma.”

– S. VINCENT RAJKUMAR, MD
Mayo Clinic, Rochester, MN



The IMF’s International Myeloma Working Group (IMWG) consists of 144 leading myeloma researchers from around the world. They collaborate on a broad range of treatment issues in order to create new myeloma management guidelines that provide patients with more durable remissions and improved quality of life. The IMWG focuses on treatment

protocols and diagnostic systems, addressing the needs of both myeloma patients and the physicians who treat them. This group is also dedicated to assuring that their research results are made readily accessible to all patients, caregivers, and medical professionals, regardless of where they live or practice.

In June 2010 in Barcelona, Spain, the IMF held the inaugural Myeloma Summit, a first-of-its-kind meeting of the IMWG, with a mission to identify, support, and implement the most promising research to prevent onset of active disease, improve treatment, and find a cure for myeloma. This summit brought together 69 myeloma experts from 23 countries, representing 58 institutions, and led to recommendations addressing:

- Early high-risk smoldering myeloma;
- Sequential versus curative strategies;
- Role of autologous stem cell transplant and consolidation;
- Maintenance therapy;
- New drugs.

In addition to these broad recommendations, Myeloma Summit attendees discussed ongoing and recently conceived IMWG consensus and database projects. The group enthusiastically agreed that continued collaboration would lay the groundwork to move beyond long-term remissions and begin charting a roadmap for a cure.



Hervé Avet-Loiseau, MD, PhD
Institute de Biologie
Nantes, France

Dr. Hervé Avet-Loiseau’s first contact with the IMF was as a young researcher applying for a Brian D. Novis Senior Research Grant, an award he won in back-to-back years: 2001 and 2002.

Nine years later, Dr. Avet-Loiseau has established himself as an integral member of the myeloma research community, serving as a member of the IMF’s International Myeloma Working Group, Bank On A Cure® initiative, Scientific Advisory Board, and International Myeloma Forum.

Dr. Avet-Loiseau’s research is dedicated to the prognostication of patients with myeloma. “My interest in myeloma is focused on the genetic abnormalities that occur in the malignant plasma cells,” he explains. “I believe that these chromosomal and molecular abnormalities are the basis for patient outcome.”

Dr. Avet-Loiseau was the principal investigator for the International Myeloma Working Group’s recent project selected for oral presentation at ASH 2009, which addressed follow-up of the group’s renown International Staging System. He also co-authored one of the group’s recent papers published in *Leukemia*. Dr. Avet-Loiseau also served as a collaborator on two Bank On A Cure poster presentations also selected for ASH 2009.

He is honored that as his career has grown, so has his collaboration with the IMF. “The IMF does a great job running consensus meetings for diagnostic assessment, prognostic evaluation, and patient management,” he says. “The IMF also enables researchers to meet and discuss.”

He also looks forward to a promising future – and sees it drawing near. “My hope is that soon patients will be treated on a risk-adapted strategy. I am convinced that it we will be able to identify the best treatment strategies and targeted therapies for each patient as soon as they are diagnosed.”



Shaji Kumar, MD

Mayo Clinic
Rochester, MN

Dr. Shaji Kumar's involvement in myeloma research began while receiving his hematology/oncology training at the Mayo Clinic. "All the myeloma physicians at Mayo have been closely involved with the IMF," Dr. Kumar says. "As a result, I was exposed to the IMF's work early in my career. Since then I've considered the IMF a key partner in improving the care of myeloma patients."

Dr. Kumar's research focuses on disease evolution and the mechanisms underlying disease progression, with a specific interest in the marrow microenvironment. "In the laboratory, we study how new drugs work and focus on developing new drug combinations," he explains. "The goal is to develop treatment strategies based on a better understanding of disease biology."

As a member of the IMF's International Myeloma Working Group, Dr. Kumar was the principal investigator for two of the group's recent projects selected for presentation at ASH 2009 and ASCO 2010. Additionally, he co-authored two of the group's papers recently published in *Leukemia*. Dr. Kumar also serves as a member of the IMF's International Myeloma Forum and is actively involved in multiple clinical trials evaluating novel drugs and combinations.

Dr. Kumar sees a promising future for myeloma research and the patients and families his work affects. "The paradigm has started changing to one of chronic disease control in a good number of patients," he says. "We are making headway into understanding the heterogeneity of the disease and individualizing therapy."

He also sees the IMF's role as continuing to be a unique and crucial one. "The IMF fosters relationships between collaborators, develops research projects that allow data collection from multiple centers – otherwise difficult to do – and serves as the patients' voice," Dr. Kumar says. "The IMF brings everyone together under one roof, with the common goal of improving outcomes for patients and eventually curing this disease."

Long-term IMWG research collaboration also led to three publications during October 2009 through September 2010:

International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

S Giralt, EA Stadtmauer, JL Harousseau, A Palumbo, W Bensinger, RL Comenzo, S Kumar, NC Munshi, A Dispenzieri, R Kyle, G Merlini, J San Miguel, H Ludwig, R Hajek, S Jagannath, J Blade, S Lonial, MA Dimopoulos, H Einsele, B Barlogie, KC Anderson, M Gertz, M Attal, P Tosi, P Sonneveld, M Boccadoro, G Morgan, O Sezer, MV Mateos, M Cavo, D Joshua, I Turesson, W Chen, K Shimizu, R Powles, PG Richardson, R Niesvizky, SV Rajkumar, and BG Durie on behalf of the IMWG

Leukemia. 2009 Oct 23(10):1904-12. Epub 2009 Jun 25.

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

A Palumbo, O Sezer, R Kyle, JS Miguel, RZ Orlowski, P Moreau, R Niesvizky, G Morgan, R Comenzo, P Sonneveld, S Kumar, R Hajek, S Giralt, S Brinchen, KC Anderson, PG Richardson, M Cavo, F Davies, J Bladé, H Einsele, MA Dimopoulos, A Spencer, A Dispenzieri, T Reiman, K Shimizu, JH Lee, M Attal, M Boccadoro, M Mateos, W Chen, H Ludwig, D Joshua, V Hungria, I Turesson, BG Durie, and S Lonial on behalf of the IMWG

Leukemia. 2009 Oct 23(10):1716-30. Epub 2009 Jun 4. Review.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

R Fonseca, PL Bergsagel, J Drach, J Shaughnessy, N Gutierrez, AK Stewart, G Morgan, B Van Ness, M Chesi, S Minvielle, A Neri, B Barlogie, WM Kuehl, P Liebisch, F Davies, S Chen-Kiang, BG Durie, R Carrasco, O Sezer, T Reiman, L Pilarski, H Avet-Loiseau; International Myeloma Working Group.

Leukemia. 2009 Dec 23(12):2210-21. Epub 2009 Oct 1.

The American Society of Hematology (ASH) selected two IMWG research projects for presentation at its December 2009 conference in New Orleans, LA:

Oral presentation:

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients

H Avet-Loiseau, BG Durie, J Haessler, J Crowley, A Hoering, B Barlogie, JD Shaughnessy, O Sezer, C Shustik, R Hajek, H Goldschmidt, P Sonneveld, P Moreau, M Attal, A Palumbo, M Boccadoro, J Hoon Lee, J Westin, I Turesson, JF San Miguel, J Blade, JJ Lahuerta, S Pavlovsky, DB Fantl, SV Rajkumar, and R Fonseca

Poster presentation:

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study

S Kumar, J Blade, J Crowley, H Goldschmidt, A Hoering, S Jagannath, JJ Lahuerta, J Laubach, P Moreau, G Morgan, RZ Orlowski, A Palumbo, P Richardson, JF San Miguel, O Sezer, D Siegel, P Sonneveld, J Szymonifka, SV Rajkumar, and BG Durie

The American Society of Clinical Oncology conference selected an additional IMWG study for poster presentation at its June 2010 conference:

Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.

S Kumar, J Crowley, SK Klein, JJ Lahuerta, J Lee, P Moreau, G Morgan, PG Richardson, D Siegel, BG Durie, on behalf of the IMWG

International Myeloma Working Group

Brian G.M. Durie, MD, Co-Leader

Cedars-Sinai Samuel Oschin Cancer Center
Aptium Oncology, Inc.
Los Angeles, CA, USA

S. Vincent Rajkumar, MD, Co-Leader

Mayo Clinic
Rochester, MN, USA

Niels Abildgaard, MD
Syddansk Universitet
Odense, Denmark

Rafat Abonour, MD
Indiana University School of Medicine
Indianapolis, IN, USA

Raymond Alexanian, MD
MD Anderson Cancer Center
Houston, TX, USA

Melissa Alsina, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Michel Attal, MD
Hôpital Purpan
Toulouse, France

Hervé Avet-Loiseau, MD, PhD
Institut de Biologie
Nantes, France

Ashraf Z. Badros, MD
University of Maryland
Baltimore, MD, USA

Dalsu Baris, PhD
National Cancer Institute
Rockville, MD, USA

Bart Barlogie, MD, PhD
Myeloma Institute for Research and Therapy, UAMS
Little Rock, AK, USA

Régis Bataille, MD
Institute of Biology
Nantes, France

Meral Beksac, MD
Ankara University
Ankara, Turkey

Andrew Belch, MD
University of Alberta
Edmonton, Canada

William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

Dina Ben-Yehuda, MD
Hadassah University Hospital
Jerusalem, Israel

P. Leif Bergsagel, MD
Mayo Clinic Scottsdale
Scottsdale, AZ, USA

Jenny Bird, MD
Bristol Haematology & Oncology Centre
Bristol, UK

Joan Bladé, MD
Hospital Clinic, Hematology
Barcelona, Spain

Mario Boccardo, MD
Ospedale Molinette
Torino, Italy

Michele Cavo, MD
Università di Bologna
Bologna, Italy

Asher Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY, USA

Wen-Ming Chen, MD
Beijing Chaoyang Hospital
Beijing, China

Marta Chesi, PhD
Mayo Clinic

Scottsdale, AZ, USA

J. Anthony Child, MD
Barn House
Chilgrove, UK

James Chim, MD
Queen Mary Hospital
Hong Kong

Wee-Joo Chng, MD
National University Health System
Republic of Singapore

Raymond L. Comenzo, MD
Tufts Medical School of Medicine
Boston, MA, USA

John Crowley, PhD
Cancer Research and Biostatistics
Seattle, WA, USA

William Dalton, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, FL, USA

Faith Davies, MD
Royal Marsden
NHS Foundation Trust
Sutton, UK

Cármelo de Souza, MD, PhD
State University of Campinas
Campinas, Brazil

Michel Delforge, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Meletios Dimopoulos, MD
University of Athens
School of Medicine
Athens, Greece

Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN, USA

Johannes Drach, MD
University of Vienna
Vienna, Austria

Matthew Drake, MD, PhD
Mayo Clinic
Rochester, MN, USA

Hermann Einsele, MD
University Clinic of Würzburg
Würzburg, Germany

Thierry Facon, MD
Centre Hospitalier Regional
Lille, France

Dorotea Fantl, MD
Sociedad Argentina de Hematología
Buenos Aires, Argentina

Jean-Paul Fermand, MD
Hôpital Saint-Louis
Paris, France

Rafael Fonseca, MD
Mayo Clinic Scottsdale
Scottsdale, AZ, USA

Gösta Gahrton, MD
Karolinska Institute
Stockholm, Sweden

Ramón García-Sanz, MD
University of Salamanca
Salamanca, Spain

Christina Gasparetto, MD
Duke University Medical School
Raleigh-Durham, NC, USA

Morie A. Gertz, MD
Mayo Clinic
Rochester, MN, USA

John Gibson, MD
Royal Prince Alfred Hospital
Camperdown, Australia

Sergio Giral, MD
MD Anderson Cancer Center
Houston, TX, USA

Hartmut Goldschmidt, MD
University of Heidelberg
Heidelberg, Germany

Philip Greipp, MD
Mayo Clinic
Rochester, MN, USA

Roman Hájek, MD
University Hospital Brno
Brno, Czech Republic

Izhar Hardan, MD
Chaim Sheba Medical Center
Tel Hashomer, Israel

Parameswaran Hari, MD
Medical College of Wisconsin
Milwaukee, WI, USA

Hiroyuki Hata, MD, PhD
Kumamoto University Hospital
Kumamoto, Japan

Yutaka Hattori, MD
Keio University
School of Medicine
Tokyo, Japan

Tom Heffner, MD
Emory University
Atlanta, GA, USA

Joy Ho, MD
Royal Prince Alfred Hospitals & Concord Hospitals
Camperdown, Australia

Vania Hungria, MD
Clinica São Germano
São Paulo, Brazil

Shinsuke Iida, MD
Nagoya City University Graduate School of Medical Sciences
Nagoya, Japan

Peter Jacobs, MD
Constantiaberg Medi-Clinic
Cape Town, South Africa

Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY, USA

Hou Jian, MD
Shanghai Changzheng Hospital
Shanghai, China

Hans Johnsen, MD
Aalborg Sygehus
Aalborg, Denmark

Douglas Joshua, MD
University of Sydney
Sydney, Australia

Artur Jureczyszyn, MD, PhD
The Myeloma Treatment Foundation
Krakow, Poland

Jonathan Kaufman, MD
Emory University, School of Medicine
Atlanta, GA, USA

Michio M. Kawano, MD
Yamaguchi University
Yamaguchi, Japan

Amrita Krishnan, MD
City of Hope
Duarte, CA, USA

Nicolas Kröger, MD
University Hospital Hamburg
Hamburg, Germany

Eva Kovacs, MD
Cancer Immunology Research-Life
Birsfelden, Switzerland

Shaji Kumar, MD
Mayo Clinic
Rochester, MN, USA

Robert A. Kyle, MD
Mayo Clinic
Rochester, MN, USA

Martha Lacy, MD
Mayo Clinic
Rochester, MN, USA

Juan Lahuerta, MD
Hospital Universitario
12 de Octubre
Madrid, Spain

Ola Landgren, MD
National Cancer Institute,
National Institutes of Health
Rockville, MD, USA

Jacob Laubach, MD
Dana Farber Cancer Institute
Boston, MA, USA

Jae Hoon Lee, MD
Gachon University Medical School
Incheon, Republic of Korea

Xavier LeLeu, MD
Hôpital Claude Huriez
Lille, France

Suzanne Lentzsch, MD
University of Pittsburgh
Pittsburgh, PA, USA

Henk M. Lokhorst, MD
University Hospital Utrecht
Utrecht, The Netherlands

Sagar Lonial, MD
Emory University
School of Medicine
Atlanta, GA, USA

Heinz Ludwig, MD
Wilhelminenspital der Stadt Wien
Vienna, Austria

Angelo Maiolino, MD
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil

Maria Victoria Mateos, MD
University Hospital of Salamanca
Salamanca, Spain

Amitabha Mazumder, MD
NYU Comprehensive Cancer Center
New York, NY, USA

Philip McCarthy, MD
Roswell Park Cancer Center
New York, NY, USA

Jayesh Mehta, MD
Northwestern University
Chicago, IL, USA

Ulf-Henrik Mellqvist, MD
Sahlgrenska University Hospital
Gothenburg, Sweden

GiamPaolo Merlini, MD
Amyloidosis Center,
Università di Pavia
Pavia, Italy

Joseph Mikhael, MD
Mayo Clinic Scottsdale
Scottsdale, AZ, USA

Angelina Rodríguez Morales, MD
Hemato-Oncology Clinic
Caracas, Venezuela

Philippe Moreau, MD
University Hospital of Nantes
Nantes, France

Gareth Morgan, MD, PhD
Royal Marsden Hospital
Sutton, UK

Nikhil Munshi, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Hareth Nahi, MD
Karolinska University Hospital
Stockholm, Sweden

Ruben Niesvizky, MD
Weill Medical College of Cornell University
New York, NY, USA

Amara Nouel, MD
Hospital Rutz y Paez
Bolívar, Venezuela

Yana Novis, MD
Hospital Sirio-Libanês
São Paulo, Brazil

Robert Orlowski, MD
MD Anderson Cancer Center
Houston, TX, USA

Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy

Santiago Pavlovsky, MD
FUNDALU
Buenos Aires, Argentina

Linda Pilarski, MD
Cross Cancer Institute
Edmonton, Canada

Raymond Powles, MD
Parkside Oncology Clinic
London, UK

Noopur Raje, MD
Massachusetts General Hospital
Boston, MA, USA

Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada

Tony Reiman, MD
Cross Cancer Institute
Edmonton, Canada

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, MA, USA

David Roodman, MD
University of Pittsburgh
School of Medicine
Pittsburgh, PA, USA

Laura Rosiñol, MD
Hospital Clinic
Barcelona, Spain

Stephen Russell, MD, PhD
Mayo Clinic
Rochester, MN, USA

Jesús San Miguel, MD
Hospital Clínico Universitario
Salamanca, Spain

Sabina Sevcikova, PhD
Masaryk University
Brno, Czech Republic

Orhan Sezer, MD
University of Hamburg
Hamburg, Germany

Jatin Shah, MD
MD Anderson Cancer Center
Houston, Texas, USA

John Shaughnessy, PhD
Myeloma Institute for Research and Therapy, UAMS
Little Rock, AK, USA

Kazuyuki Shimizu, MD
Nagoya City Higashi General Hospital
Nagoya, Japan

Chaim Shustik, MD
Royal Victoria Hospital
Montreal, Canada

David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ, USA

Seema Singhal, MD
Northwestern University
Chicago, IL, USA

Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, The Netherlands

Andrew Spencer, MD
The Alfred Hospital
Melbourne, Australia

Edward Stadtmauer, MD
University of Pennsylvania
Philadelphia, PA, USA

A. Keith Stewart, MD
Mayo Clinic Scottsdale
Scottsdale, AZ, USA

Evangelos Terpos, MD
University of Athens School of Medicine and Imperial College London
London, UK.

Patrizia Tosi, MD
Istituto di Ematologia e Oncologia Medica
Bologna, Italy

Guido Tricot, MD
Huntsman Cancer Institute
Salt Lake City, UT, USA

Ingemar Tureson, MD
SKANE University Hospital
Malmö, Sweden

Saad Usmani, MD
Myeloma Institute for Research and Therapy, UAMS
Little Rock, AR, USA

Benjamin Van Camp, MD, PhD
Huntsman Cancer Institute
Free University Brussels
Brussels, Belgium

Brian Van Ness, PhD
University of Minnesota
Minneapolis, MN, USA

Ivan Van Riet, MD
Academic Hospital
Free University Brussels
Brussels, Belgium

Isabelle Vande Broek, MD
Vrije Universiteit Brussel
Brussels, Belgium

Karin Vanderkerken, PhD
Vrije Universiteit Brussel
Brussels, Belgium

Robert Vescio, MD
Cedars-Sinai
Outpatient Cancer Center
Los Angeles, CA, USA

David Vesole, MD
Hackensack University Medical Center
Hackensack, NJ, USA

Peter Voorhees, MD
University of North Carolina
Chapel Hill, NC, USA

Anders Waage, MD
St. Olavs Hospital
Trondheim, Norway

Michael Wang, MD
MD Anderson Cancer Center
Houston, TX, USA

Donna Weber, MD
MD Anderson Cancer Center
Houston, TX, USA

Jan Westin, MD
Sahlgrenska University Hospital
Gothenburg, Sweden

Keith Wheatley, PhD
University of Birmingham,
Edgbaston
Birmingham, UK

Elena Zamagni, MD
University of Bologna
Bologna, Italy

Jeffrey Zonder, MD
Wayne State University
School of Medicine
Detroit, Michigan, USA





Robert A. Kyle Lifetime Achievement Award

On June 9, 2010 in Barcelona, Spain, the Robert A. Kyle Lifetime Achievement Award was presented to Joan Bladé, Senior Consultant and Director of Myeloma Programs at the Hospital Clinic de Barcelona. The IMF joined with 50 international myeloma clinicians and researchers for a dinner ceremony in Dr. Bladé's honor, raising \$50,000 for IMF research.



Drs. Joan Bladé and Robert Kyle

EIGHTH ANNUAL INTERNATIONAL MYELOMA FOUNDATION
ROBERT A. KYLE
LIFETIME ACHIEVEMENT AWARD

Bank On A Cure®

Bank On A Cure (BOAC) is the world's first global, myeloma-specific DNA bank and research initiative. Using the IMF's own custom-designed gene-testing chip, BOAC scientists are poring over vast amounts of genetic information the IMF has gathered from myeloma patients worldwide in order to determine common genetic factors. Through finding and studying these commonalities, researchers will be able to develop and tailor more effective treatment options and minimize treatment side effects. Discovering these genetic patterns will also unlock the mysteries of what causes myeloma – and ultimately lead to its cure.



The December 2009 ASH conference selected four BOAC research projects for presentation:

Oral Presentation:

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations

DC Johnson, WM Gregory, N Dickens, B Walker, A Szubert, F Davies, BG Durie, BG Van Ness, and GJ Morgan

Poster Presentations:

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients

R Kuiper, SL Corthals, P Hanifi-Moghaddam, Y de Knecht, H Lokhorst, H Goldschmidt, BG Durie, BG Van Ness, GJ Morgan, M van Duin, H Avet-Loiseau, and P Sonneveld

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma

SL Corthals, DC Johnson, Y de Knecht, H Goldschmidt, H Lokhorst, S Minivieille, F Magrangeas, J Harousseau, BG Durie, BG Van Ness, GJ Morgan, P Sonneveld, and H Avet-Loiseau

Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma

SL Corthals, H Goldschmidt, DC Johnson, H Lokhorst, Y de Knecht, S Zweegman, B van der Holt, D Hose, MJ Kersten, E Vellenga, BG Duire, GJ Morgan, and P Sonneveld

From October 2009 through September 2010, BOAC researchers also continued its epidemiology plan and pursued SNP testing addressing peripheral neuropathy, research leading to publication in late 2010 (to be discussed further in next year's annual report).

Bank On A Cure® Research Team

Gareth Morgan, MD, Co-Chair
Royal Marsden Hospital
Sutton, UK

Brian Van Ness, MD, PhD, Co-Chair
University of Minnesota
Institute of Human Genetics
Minneapolis, MN, USA

Hervé Avet-Loiseau, MD
Institute de Biologie
Nantes, France

Dalsu Baris, MD, PhD
National Cancer Institute
Rockville, Maryland, USA

John Crowley, PhD
Cancer Research and Biostatistics
Seattle, WA, USA

Brian G.M. Durie, MD
Cedars-Sinai Outpatient Cancer Center
Aptium Oncology, Inc.
Los Angeles, CA, USA

Hartmut Goldschmidt, MD
University of Heidelberg
Heidelberg, Germany

Roman Hájek, MD
University Hospital Brno
Brno, Czech Republic

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN, USA

Jesús San Miguel, MD
Hospital Clínico Universitario
Salamanca, Spain

John Shaughnessy, PhD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, AR, USA

Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, The Netherlands

Research Grants Program

Through its Research Grants Program, the IMF remains at the forefront of identifying, supporting, and developing the world's most promising myeloma research. The IMF backs both junior and senior researchers, funding 104 grants since the program's inception in 1994. This IMF-supported work continues to lead to further funding from other highly regarded institutions and more than 250 publications in the world's top research journals.



(Research Grants continues on next page)

“The Brian D. Novis Research Grant was the first grant I was awarded. Thanks to the IMF, I was able to focus one entire year on myeloma research, and my work allowed me to successfully apply for a faculty position where I will continue my career as an independent researcher focused on myeloma.”

– ARIOSTO SILVA, PhD
H. Lee Moffitt Cancer and Research Institute, Tampa, FL

IMF Scientific Advisory Board

Raymond Alexanian, MD
MD Anderson Cancer Center
Houston, TX, USA

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Michel Attal, MD
Hôpital Purpan
Toulouse, France

Hervé Avet-Loiseau, MD, PhD
Institut de Biologie
Nantes, France

Dalsu Baris, MD, PhD
National Cancer Institute
Rockville, Maryland, USA

Bart Barlogie, MD, PhD
Myeloma Institute
for Research and Therapy
Little Rock, AR, USA

Régis Bataille, MD
Institut de Biologie
Nantes, France

Meral Beksac, MD
Ankara University
Ankara, Turkey

William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

James R. Berenson, MD
Institute for Myeloma &
Bone Cancer Research
Los Angeles, CA, USA

P. Leif Bergsagel, MD
Mayo Clinic
Scottsdale, AZ, USA

Joan Bladé, MD
Hospital Clinic, Hematology
Barcelona, Spain

Mario Boccadoro, MD
Cattedra Di Ematologia
Torino, Italy

J. Anthony Child, MD
Barn House
Chilgrove, UK

Raymond L. Comenzo, MD
Memorial Sloan Kettering
Cancer Research Center
New York, NY, USA

John Crowley, PhD
Cancer Research and Biostatistics
Seattle, WA, USA

Franco Dammacco, MD
University of Bari Medical School
Bari, Italy

Faith Davies, MD
Royal Marsden NHS Foundation Trust
Sutton, UK

Meletios Dimopoulos, MD
University of Athens School of Medicine
Athens, Greece

Johannes Drach, MD
Medical University of Vienna
Vienna, Austria

Brian G.M. Durie, MD
Cedars-Sinai Samuel Oschin
Cancer Center
Aptium Oncology, Inc.
Los Angeles, CA, USA

Hermann Einsele, MD
University Clinic of Würzburg
Würzburg, Germany

Dorotea Fantl, MD
Sociedad Argentina de Hematología
Buenos Aires, Argentina

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, AZ, USA

Gösta Gahrton, MD
Karolinska Institute
Stockholm, Sweden

Morie A. Gertz, MD
Mayo Clinic
Rochester, MN, USA

John Gibson, MD
Royal Prince Alfred Hospital
Camperdown, Australia

Hartmut Goldschmidt, MD
Medical Klinik und Poliklinik V
University of Heidelberg
Heidelberg, Germany

Roman Hájek, MD
University Hospital Brno
Brno, Czech Republic

Joy Ho, MD
Royal Prince Alfred Hospitals
and Concord Hospitals
Camperdown, Australia

Vania Hungria, MD
Clinica São Germano
São Paulo, Brazil

Sundar Jagannath, MD
St. Vincent's Comprehensive
Cancer Center
New York, NY, USA

Douglas Joshua, MD
University of Sydney
Sydney, Australia

Michio M. Kawano, MD
Yamaguchi University
Yamaguchi, Japan

Robert A. Kyle, MD, Chairman
Mayo Clinic
Rochester, MN, USA

Henk M. Lokhorst, MD
University Hospital Utrecht
Utrecht, Netherlands

Sagar Lonial, MD
Emory Winship Cancer Institute
Atlanta, GA, USA

Heinz Ludwig, MD
Wilhelminenspital der Stadt Wien
Vienna, Austria

Jayesh Mehta, MD
Robert H. Lurie Comprehensive
Cancer Center
Chicago, IL, USA

Håkan Mellstedt, MD, PhD
Karolinska Hospital
Stockholm, Sweden

Giampaolo Merlini, MD
Amyloidosis Centre
Università di Pavia
Pavia, Italy

Gareth Morgan, MD, PhD
Royal Marsden Hospital
Sutton, UK

Nikhil Munshi, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Amara Nouel, MD
Hospital Rutz y Paez
Bolivar, Venezuela

Martin Oken, MD
Hubert H. Humphrey Cancer Center
Robbinsdale, MN, USA

Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy

Linda Pilarski, MD
Cross Cancer Institute
Edmonton, Canada

Raymond Powles, MD
Parkside Oncology Clinic
London, UK

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN, USA

Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Angelina Rodriguez Morales, MD
Banco Municipal de Sangre
de la Region Capital
Caracas, Venezuela

David Roodman, MD
VA Medical Hospital
Pittsburgh, PA, USA

Jesús San Miguel, MD
Hospital Clinico Universitario
Salamanca, Spain

Orhan Sezer, MD
University of Hamburg
Hamburg, Germany

Kazayuki Shimizu, MD
Nagoya City Higashi General Hospital
Nagoya, Japan

Chaim Shustik, MD
Royal Victoria Hospital
McGill University
Clinical Research Program
Montreal, Canada

David Siegel, MD
Hackensack University
Medical Center
Hackensack, NJ, USA

Seema Singhal, MD
Robert H. Lurie Comprehensive
Cancer Center
Northwestern University
Chicago, IL, USA

Alan Solomon, MD
University of Tennessee
Medical Center
Knoxville, TN, USA

Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, The Netherlands

Andrew Spencer, MD
The Alfred Hospital
Melbourne, Australia

A. Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA


Guido Tricot, MD
Huntsman Cancer Institute
Salt Lake City, UT, USA

Benjamin Van Camp, MD, PhD
Academic Hospital
Free University of Brussels
Brussels, Belgium

Brian Van Ness, MD, PhD
University of Minnesota
Institute of Human Genetics
Minneapolis, MN, USA

David Vesole, MD, PhD
Hackensack University
Medical Center
Hackensack, NJ, USA

Jan Westin, MD
Sahlgrenska University Hospital
Gothenburg University
Gothenburg, Sweden



Vyacheslav Yurchenko, PhD
Rockefeller University
Laboratory of Lymphocyte Signaling
New York, NY

Vyacheslav Yurchenko is a 2010 Brian D. Novis Junior Research Grant recipient for his work, *MMSET and epigenetic control in t(4;14) myelomas*. Recent findings suggest an important role of the histone methyl-transferase MMSET (multiple myeloma SET domain protein) in malignant progression of myeloma. Dr. Yurchenko's research sets out to define the role of MMSET in normal plasma and myeloma cell development, and to identify the genetic network directly controlled by MMSET in B cells.

Dr. Yurchenko's research was already in progress when he learned about an IMF research grant opportunity. "I did an Internet search for some potential funding sources, and I came across the announcement for the IMF grants," he recalls. "I felt that the IMF particularly related to me and my project because, if successful, my research can lead to better treatment, diagnosis, and prevention of myeloma."

Although Dr. Yurchenko's research is based in a laboratory, what excites him most about his work is its potential practical applications. "My project is translational in its nature," he explains. "I am doing basic science research that can – and, I hope, will – be translated into something useful for clinical medicine."

Dr. Yurchenko has made significant progress. He has created an animal model that potentially can be used to understand underlying principles of myeloma disease initiation and progression. It could also be used to test chemical compounds with anti-myeloma activity. The model is being tested now, with further IMF support – Dr. Yurchenko is also a 2011 Brian D. Novis Grant recipient.

He is happy to continue the relationship. "The IMF staff is very committed and helpful to me as a scientist, and it is a great organization fighting for a great cause."

In December 2009, the IMF announced its six 2010 research grant recipients, supporting them with a total of \$355,000:

Brian D. Novis Senior Research Grants 2010



- **Aaron Schimmer, MD, PhD, FRCPC**
Princess Margaret Hospital, Ontario Cancer Institute
Toronto, Canada
Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma

Brian D. Novis Junior Research Grants 2010



- **Xin Li, PhD**
Myeloma Institute for Research and Therapy
Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, AR, USA
Mesenchymal cell cytotrophy for multiple myeloma



- **Eline Menu, PhD**
Vrije Universiteit Brussel
Brussels, Belgium
Characterization and preclinical evaluation of NKT cells in multiple myeloma



- **Steffan Nawrocki, PhD**
The University of Texas Health Sciences Center
San Antonio, TX, USA
Reolysin: a novel reovirus-based therapy for multiple myeloma



- **Ariosto Silva, PhD**
H. Lee Moffitt Cancer and Research Institute
Tampa, FL, USA
Bone marrow microenvironment and multiple myeloma chemotherapy optimization



- **Vyacheslav Yurchenko, PhD**
Laboratory of Lymphocyte Signaling
Rockefeller University
New York, NY, USA
MMSET and epigenetic control in t(4;14) myelomas

IMF Japan Aki Award 2010



- **Junya Kuroda, MD, PhD**
Division of Hematology and Oncology
Kyoto Prefectural University
Kyoto, Japan
Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins

Global Clinical Trials Forum

The IMF's Global Clinical Trials Forum was created to enhance the collaboration and cooperation between national and international myeloma research groups in order to improve clinical trial design and data accrual. In 2010, the efforts of this 32-member group led to the establishment of a myeloma-specific Cancer Therapy Evaluation Program at the National Cancer Institute, a goal set forth in last year's agenda.

This year, the Global Clinical Trials Forum convened at the ASH conference in December 2009, setting an agenda to work with the Food and Drug Administration in order to accelerate new drug approvals and reach agreement on required comparator studies.

Global Clinical Trials Forum

Kenneth C. Anderson, MD
Dana Farber Cancer Institute
Boston, MA, USA

Hervé Avet-Loiseau, MD
Institutes of Biologie
Nantes, France

Michel Attal, MD
Hospital Purpan
Toulouse, France

Bart Barlogie, MD
University of Arkansas
for Medical Sciences
Myeloma Institute
for Research Therapy
Little Rock, AR, USA

William Bensinger, MD
University of Washington
Fred Hutchinson
Cancer Research Center
Seattle, WA, USA

Joan Bladé, MD
Hospital Clinica
Barcelona, Spain

Mario Boccadoro, MD
Cattedra Di Ematologia
Torino, Italy

Ivan Borrello, MD
Johns Hopkins University
Sidney Kimmel Comprehensive
Cancer Center
Baltimore, MD, USA

John Crowley, PhD
Cancer Research and Biostatistics
Seattle, WA, USA

Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN, USA

Brian G.M. Durie, MD
Cedars-Sinai Samuel Oschin
Cancer Center
Aptium Oncology, Inc.
Los Angeles, CA, USA

Morie A. Gertz, MD
Mayo Clinic
Rochester, MN, USA

Sergio Giralt, MD
University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Roman Hájek, MD
University Hospital Brno
Brno, Czech Republic

Vania Hungria, MD
Clinica São Germano
São Paulo, Brazil

Sundar Jagannath, MD
St. Vincents Comprehensive
Cancer Institute
New York, NY, USA

Shaji Kumar, MD
Mayo Clinic Rochester
Rochester, MN, USA

Robert A. Kyle, MD
Mayo Clinic Rochester
Rochester, MN, USA

Ola Landgren, MD
National Cancer Institute,
National Institutes of Health
Rockville, MD, USA

Jae-Hoon Lee, MD
Gachon University
Gil Hospital
Incheon, Republic of Korea

Richard F. Little, MD
CTEP/DCTD/NCI
Bethesda, MD USA

Sagar Lonial, MD
Emory University
Winship Cancer Institute
Atlanta, GA, USA

Heinz Ludwig, MD
Wilhelminenspital der Stadt Wien
Vienna, Austria

Gareth Morgan, MD, PhD
Royal Marsden Hospital
Sutton, UK

Nikhil Munshi, MD
Dana-Farber Cancer Institute
Boston, MA, USA

Antonio Palumbo, MD
Università di Torino
Torino, Italy

S. Vincent Rajkumar, MD
Mayo Clinic Rochester
Rochester, MN, USA

Donna Reece, MD
Princess Margaret Hospital
Toronto, Canada

Jesús San Miguel, MD
Hospital Clínico Universitario
Salamanca, Spain

Kazuyuki Shimizu, MD
Nagoya City Higashi General Hospital
Nagoya, Japan

Seema Singhal, MD
Northwestern University
Medical School
Chicago, IL, USA

Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, The Netherlands

Edward Stadtmauer, MD
University of Pennsylvania
Philadelphia, PA, USA

A. Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA

Howard Streicher, MD
National Cancer Institute
Cancer Therapy Evaluation Program
Rockville, MD, USA

Robert Vescio, MD
Cedars-Sinai Comprehensive
Cancer Center
Los Angeles, CA, USA

Our collaborative research extends worldwide.



In this bird's-eye view, the colored dots represent the locations where IMF research programs take place all around the globe.



David Miller
Northfield, MA

In October 2003, David Miller went for a routine annual physical. But his internist noted something far from routine – unusual protein readings in Dave’s blood work led to a prompt diagnosis of myeloma. “I later learned that many internists would have ignored the anomalies,” Dave says. “I am very grateful that my myeloma was found quite early, when the disease had not had time to do much pre-treatment damage.”

For more than five years Dave was successfully treated by a general oncologist in Washington, DC, but in 2009 he was looking to make a change. He wanted to keep his appointments much closer to home and, more importantly, “I felt I had reached a point where some new and different treatment seemed advisable,” he says.

Dave found the IMF website (myeloma.org) while seeking information about myeloma specialists in his area and took the opportunity to contact the IMF’s Hotline (800-452-CURE). “I had contacted two or three other organizations by phone and got only a limited response,” Dave recalls. “But with the IMF I got a pro-active response. The Hotline was completely engaged in my case, asked a series of focused and relevant questions, and strongly endorsed my plan to seek a myeloma expert.”

The IMF Hotline provided Dave with several referrals. After meeting with his options, he called the Hotline once again. “They could not have been more helpful to my ‘sorting out’ process, and providing sound counsel on all my issues at the time,” he says.

The new specialist Dave selected was the one the Hotline felt was the strongest choice for him from the start. “She has treated me with clinical and ‘human’ excellence since August 2009,” Dave reports. “I could not be more satisfied with the IMF response and ultimate recommendation.”

SUPPORT

“Whether we are newly diagnosed or long-term survivors, it always helps to know that we are not alone on our journey.”

– PAT LAAS, Bettendorf, IA

The IMF remains dedicated to ensuring that no one feels isolated by a myeloma diagnosis. The IMF’s programs and services are designed to provide patients and their loved ones with a strong network of local and global support and easy access to up-to-date information.

myeloma.org

“With so much misinformation flying over the Internet, it is so nice to have a ‘place of reason’ to get accurate, timely knowledge.”

– NANCY RHYME, San Clemente, CA

The IMF website is a hub for everything the IMF has to offer.* With 24-hour access to the IMF’s comprehensive publications, videos, blogs, research updates, and the latest community developments, it is a crucial resource for patients, families, caregivers, and health care professionals throughout the world.

From October 2009 through September 2010, nearly 353,000 visitors went to myeloma.org, tallying nearly 1,400,000 page views. IMF-produced videos brought 53,500 views of 200 unique interviews and presentations. Website visitors viewed and downloaded almost 48,000 documents. During this time period, the IMF’s website was also visited via nearly 6,200 mobile devices.



Toll-Free Hotline

“The counsel I have gotten from the IMF Hotline has been outstanding – everything from handholding and encouragement to medical pointers and answers to very specific technical questions.”

– CHARTY BASSETT, ESCONDIDO, CA

The IMF’s Toll-Free Hotline provides life-saving and life-changing myeloma treatment and management support from compassionate, highly trained specialists. With a commitment in making hotline specialists as available to the community as



possible, in April 2010, the IMF added a new feature where clicking on telephone icon on the IMF website triggers a timely “return” phone call from the Hotline to the number provided. From October 2009 through September 2010, the hotline supported 2,457 callers and responded to 2,000 emails.

Support Groups

“We are just so comforted and grateful, knowing that expert advice from the compassionate members of the IMF team is guiding us through the myeloma journey.”

– CAROL MURRAY-ROSSI, Support Group Leader, Warwick, RI

Through a global community of IMF-assisted support groups, the IMF seeks to ensure that patients and families have local access to support, information, and a strong sense of collective identity. The IMF currently supports 114 groups in the United States. From October 2009 through September 2010, the IMF facilitated the formation of the first Spanish language group, based in Los Angeles, CA. In total, 14 new U.S.-based groups were formed in: Boca Raton, FL; Columbia, SC; Dayton, OH; Eau Claire, WI; Fayetteville, NC; Jackson, MS; Los Angeles, CA; Montgomery, AL; Naples, FL; Richmond, KY; Richmond, VA; Shreveport/Bossier City, LA; South Bend, IN; Springfield, MO.

The IMF is dedicated to overseeing the needs of these groups and their leaders. From October 2009 through September 2010, IMF staff visited 95 percent of its U.S.-based groups at least once, and 50 percent of these groups at least twice.




In addition, the IMF's 11th annual Support Group Leaders' Summit took place in July 2010 in Irving, TX. A total of 67 Support Group Leaders representing 52 groups attended the summit, including 16 leaders who attended for the first time. Participants were updated on the latest information about myeloma treatment and care, and provided with new leadership tools and approaches – all to further enhance the experience for their support groups back home.

Myeloma Manager™

The IMF's Myeloma Manager™ Personal Care Assistant™ is a computer program that tracks a patient's individual laboratory results and also displays and prints charts to show how these results change over time. This is an unprecedented way for patients to fully understand their own personal trends and assess progress over an extended period, helping them and their caregivers maximize the growing wealth of information and constantly increasing complexity of myeloma treatment programs.

The Myeloma Manager is available for download, free of charge, through the IMF website.

From October 2009 through September 2010, this groundbreaking program was downloaded for new use 1,765 times, with an additional 75 downloads of the amyloidosis-specific version of the program.



Elliot Recht
San Diego, CA

In 1998, at age 45, Elliot Recht felt that he was in the best shape of his life. Then he received the shock of a lifetime: He was diagnosed with myeloma.

Like many others, Elliot had never heard of myeloma before his diagnosis. He felt compelled to learn, and learn fast. He was diagnosed on a Wednesday; he found the IMF on Thursday; he called the IMF's Hotline on Friday and was provided with information about a support group in San Diego. The group's monthly meeting was scheduled for that upcoming Monday night. Less than a week after his diagnosis, Elliot attended his first meeting. He was grateful to so quickly find a local community of support.

More than 12 years later, it is a community that remains integral to his life. Elliot now serves as the group's leader, succeeding founders Fred and Virginia Gloor. He relishes the “thank you” emails after successful meetings, and he is happy to be able to help new, overwhelmed members – like he once was – become more comfortable.

In both 2008 and 2009, the San Diego Multiple Myeloma Cancer Support Group was a finalist for the *San Diego Business Journal's* Health Care Champion Award. “It's a tremendous honor, because we're competing with prestigious and established health care organizations throughout the city,” Elliot says.

Elliot credits the IMF with helping build the group's success. He relies on the IMF's website (myeloma.org) for up-to-date information and participates in the IMF's webinars for more in-depth discussions. He attends Patient & Family Seminars and calls the Hotline (800-452-CURE) for resource referrals.

Elliot has also attended four Support Group Leaders' Summits. “The IMF takes that time to show appreciation for the leaders,” he says. “The IMF also provides great information for running a successful group – which benefits patients and caregivers everywhere.”

* The IMF changed its website tracking systems at the beginning of the fiscal year.



Jerry Walton
Virginia Beach, VA

"I decided to contact our congressman in the House of Representatives because I wanted him to know about the concerns of myeloma patients in his district," says Jerry Walton, a myeloma patient diagnosed in 2006. "I also wanted to enlist his support on specific legislation that would immensely benefit myeloma and other cancer patients."

Jerry's meeting with Congressman Glenn Nye was arranged through the IMF's Advocacy Team. They augmented his idea by also scheduling meetings with both of Jerry's senators: Mark Warner and Jim Webb. "Piece of cake, to my surprise!" Jerry notes.

Jerry and the IMF Advocacy Team met with Congressman Nye himself and staff members for Senator Warner and Senator Webb in Washington, DC on March 11, 2010. After briefly discussing the nature of myeloma, the conversations shifted to legislation on the congressional docket: the Cancer Drug Coverage Parity Act (HR.2366), the Access to Clinical Trials Act (S.488 and HR.716) and the 21st Century Cancer ALERT Act (S.717). Jerry seized the opportunity to personalize the issues, using himself as an example and also sharing stories of members of the southeastern Virginia support group, which he founded in 2007 with the help of the IMF.

Great results have already been achieved thanks to the efforts of Jerry and other IMF advocates. The Access to Cancer Clinical Trials Act was ultimately included in the Patient Protection and Affordable Care Act, signed into law on March 23, 2010.

"In this wired and wireless society, the importance of communication with our legislators has never been more important," he says. "The IMF's advocacy efforts have and will continue to help us become an effective chorus with a positive influence on our leaders' healthcare decisions."

ADVOCACY

"Because of the preparation and encouragement of the IMF, I have become a believer of the power of advocacy."

– MARTI HILL, Indian Rock Beach, FL

The IMF is dedicated to creating an inclusive community that supports the wide-ranging needs of all myeloma patients, their families, their caregivers, and researchers working to combat the disease. By advocating at state and federal levels, the IMF continues to build relationships and foster change in strategic and systemic ways.

The IMF believes in including the entire myeloma community in these efforts and continues to expand its commitment to empowering patients, families and friends to advocate on their own behalf. In August 2010, the IMF created the position of Grassroots Liaison to help promote advocacy outreach and coordinate grassroots campaigns.

Governmental Policy

"Madam Speaker, I come to the floor today to help raise awareness about myeloma. . . I ask my distinguished colleagues to join me in recognizing the exemplary work being done by the IMF to improve the quality of life of myeloma patients and their families and their efforts to find a cure in the fight against cancer."

– HON. BRIAN HIGGINS, United States House of Representatives
from the Congressional Record, May 25, 2010

At the governmental level, the IMF remains committed to creating effective, immediate solutions while simultaneously building and strengthening relationships for the future. This strategy continues to bring success. IMF-supported programs received increased support during the 2010 fiscal year, including cancer research funding attached to the congressional economic stimulus package, as well as funding for programs overseen by the National Institutes of Health and the National Cancer Institute.

In August and September 2010, the U.S. Senate and House of Representatives passed the Improving Access to Clinical Trials Act, strongly advocated by the IMF and its members. This act changes current Supplemental Security Income (SSI) so that research compensation (up to \$2,000) for participation in a clinical drug study for a rare disease or condition is no longer considered income for determining SSI eligibility. (The act was formally signed into law in October 2010.) Access to trials and treatment options remains a vital issue for the myeloma community and the IMF's advocacy in this arena is more determined than ever.

IMF action was also an important component in the U.S. House of Representatives resolution declaring September 2010 as Blood Cancer Awareness Month, highlighting the impact blood cancers have in the United States and encouraging greater support for blood cancer research and education.

In April 2010, the IMF was invited to submit congressional testimony regarding fiscal year 2011 appropriations for myeloma cancer programs. From October 2009 through September 2010, the IMF also authored and co-authored 12 letters on funding and appropriations, health care reform, insurance coverage, and access to clinical trials to the Centers for Medicare & Medicaid Services, the Department of

Health and Human Services, the Employee Benefits Security Administration, and the Internal Revenue Service, as well as to nine different U.S. Senators and two members of the House of Representatives.

The IMF also empowers its individual members to claim their own voices and partners with them in bringing their stories and concerns directly to their governmental representatives. From October 2009 through September 2010, the IMF joined some of its members in meeting with Representative Glenn Nye and the staffs of Senator Barbara Boxer, Senator Mark Warner, Senator Jim Webb, and Representative Bill Young. IMF members also testified in state hearings in California, Connecticut, Maryland, Massachusetts, and New Hampshire regarding legislation for equal coverage of oral chemotherapy treatments.

Internationally, on September 9, 2010, the IMF signed an unprecedented agreement with the Chinese Health Promotion Foundation, an agency that operates under the Chinese Ministry of Health. This agreement promotes awareness of myeloma in China and encourages measures to prevent and combat the disease, substantially expanding the IMF's presence in Asia.

IMF Myeloma Awareness Month

The IMF advocates for research and treatment issues affecting the myeloma community by observing Myeloma Awareness Month. The March 2010 event included a four-part teleconference, free of charge for all listeners. Topics addressed the pillars of the IMF: Education, Research, Support and Advocacy.

Advocacy Partnerships

“On behalf of my grandfather, I was an advocate for the IMF at this year’s One Voice Against Cancer Lobby Day. People from all over the United States gathered to tell their stories to members of Congress. I will never forget the stories that were told. They made me think a little more about life itself.”

– WILLIAM CARROLL GUNTHER, IV, Aberdeen, MD

The IMF firmly believes that partnership is the strongest approach for reaching goals, and therefore proudly joins forces with other cancer organizations in order to most effectively advocate for the cancer community’s many common needs. Building these mutually beneficial relationships also ensures that myeloma patients and their families are always represented when key governmental agencies create and reflect upon their agendas.

In June 2010, the IMF once again participated in the One Voice Against Cancer (OVAC) Lobby Day in Washington, DC, organized to urge the federal government to increase funding for cancer research and prevention programs. In addition to its collaboration with OVAC, from October 2009 through September 2010, the IMF continued rewarding partnerships with the Cancer Leadership Council, the Hematological Cancers Group, the Lethal Cancer Coalition, and the National Coalition for Cancer Research, and formed new partnerships with the Alliance for a Stronger FDA and the National Organization for Rare Disorders.

The IMF Advocacy team also led an effort to form a new coalition, called the Patient Equal Access Coalition (PEAC). Comprised of advocacy groups from across the cancer spectrum – including breast, colorectal, ovarian, myeloma, and other blood cancers – the IMF and PEAC believe that every cancer patient should have access to the anticancer regimens recommended by their physicians and should not suffer from cost discrimination based on the type of therapy provided or the mechanism of delivery. PEAC is therefore dedicated to ensuring that all cancer patients have equality of access and equality of insurance coverage for all approved anticancer regimens.

IMF Advocacy Action Center

The IMF’s Advocacy Action Center is an online, centralized hub that shares governmental activity affecting the myeloma community and provides the tools for myeloma patients, families, caregivers, and medical professionals to become part of the advocacy process. When the Action Center was originally established in early 2009, this activity focused on a federal level; from October 2009 through September 2010, the IMF added state programming, which allows advocates to communicate with legislators on state-level issues.



In February 2010, the Action Center hosted two webinars, Advocacy 101 and Building Relationships with Your Members of Congress. These sessions covered building relationships with legislators, congressional visits in Washington, DC, maximizing legislative meetings, effective use of the IMF’s Advocacy Action Center, and the IMF’s 2010 public policy agenda.

From October 2009 through September 2010, nearly 1,000 new subscribers joined the IMF Advocacy Action Center’s Myeloma Action Network, an email service that alerts members when a new government representative or cause needs to be addressed by the myeloma community. Members of the Myeloma Action Network sent more than 3,000 emails to their state and federal legislators during this reporting period.

IMF Advocacy Partners

- Alliance for a Stronger FDA
- Cancer Leadership Council
- Hematological Cancers Group
- Lethal Cancer Coalition
- National Coalition for Cancer Research
- National Organization for Rare Disorders
- One Voice Against Cancer
- Patient Equal Access Coalition



Leon H. Rittenberg, Jr.
New Orleans, LA

When Leon Rittenberg Jr. was diagnosed with myeloma ten years ago, he first believed that his life expectancy would be two years, the typical statistic a newly diagnosed patient might hear. That assumption did not account for the fact that Leon was diagnosed with smoldering myeloma, nor the increasingly successful treatment options made available to all myeloma patients.

Thankfully, Leon had a knowledgeable resource at home. His wife, Cindy, spent her career as an oncology nurse, culminating as the executive director of a multi-national association for supportive care in cancer. When Cindy met the IMF at a myeloma conference, she knew it would be an important organization for her, both professionally and personally.

The Rittenbergs subsequently familiarized themselves with the IMF website and IMF-authored literature. "IMF communications are most helpful, since understanding a problem helps to give you the tools to solve it," Leon observes. "I'm a firm believer that one needs to help him or herself."

One important aspect of helping himself is through financial support of the IMF. By participating in the Founders' Circle Summit, the Rittenbergs feel they have learned a great deal more about myeloma, and feel privileged that they have had the opportunity to communicate with leading professionals in the field.

"The IMF can open doors for you," Leon says. "They do a wonderful job educating their constituency, promoting research, and financing projects."

"My family has made a significant commitment to the IMF," he continues. "Why? Really, it's to help me. But because of the IMF's educational programs and research initiatives, a valuable side effect is that our support also benefits many others."

DEVELOPMENT

"There is a direct connection between my disease and my support for the organization that does so much for so many people in the myeloma community."

– ALLAN WEINSTEIN, Paradise Valley, AZ

Since the IMF's inception 20 years ago, its mission has been to improve the quality of life for myeloma patients while working toward prevention and a cure. With that in mind, the importance of improving and expanding the IMF's core programs and services is intrinsically tied to the support received through the IMF's ongoing relationships with individual donors, corporate sponsors, and grants from pharmaceutical partners.

The results of the IMF's extensive fundraising activities provide opportunities for the myeloma community to participate in programs that offer comprehensive education, results-driven research, compassionate support services, and passionate advocates in our nation's capital for issues affecting myeloma patients and the medical professionals treating them.

All gifts, regardless of size, help fund these programs, and for this the IMF remains deeply grateful to all its donors. The support received from IMF donors makes it possible to continue all programs without any adverse effects caused by the economic recession, and the IMF continues to take pride in maintaining sure footing during a time of great economic uncertainty.

Generous donor support made it possible for the IMF to achieve all of its financial goals for the Fiscal Year. During the twelve-month period covering October 1, 2009 through September 30, 2010, the IMF raised a total of \$8.2 million in support of its programs and services. The IMF additionally received an unprecedented \$1 million through Michael McKean's win on the *Jeopardy!* Million Dollar Celebrity Invitational.

Major Gifts & Planned Giving

The IMF received 47 major gifts totaling almost \$700,000 during the 2009-10 Fiscal Year. This small group of staunch supporters makes an incredible impact on the fiscal stability of the organization through substantial and personally meaningful gifts.

Founders' Circle Summit

The IMF hosted its 3rd Annual Founders' Circle Summit on June 30, 2010. Members of the Founders' Circle, who contribute a minimum of \$10,000 annually to the IMF, were treated to in-depth briefings from IMF Chairman Dr. Brian Durie, International Myeloma Working Group Co-Leader Dr. S. Vincent Rajkumar, and Lead Principal Investigator, IMF Historical Controls Project Dr. Shaji Kumar.



Once again, the Founders' Circle Summit was conducted virtually, with presentations and interactive question-and-answer sessions with all of the experts streamed live over the Internet. By eliminating the need to travel and allowing participants to take part in this exclusive meeting from the comfort of their own homes, the event became accessible to more of the dedicated donors of the Founders' Circle.

This 3rd Annual Founders' Circle Summit raised over \$100,000 in support of the IMF research programs, including the International Myeloma Working Group.

Brian D. Novis Legacy Society

Now in its third year, the Brian D. Novis Legacy Society recognizes individuals who inform the IMF that they have made plans to include the organization in their long-term estate plans. Members of this society make bequest provisions in their will or revocable trust, or name the IMF as a beneficiary of qualified retirement plan assets (IRA or 401(K)) or life insurance policy.

The IMF sincerely wishes long, happy, and healthy lives for all myeloma patients, but also recognizes that this development strategy will yield long-term results to help to ensure the future of the IMF's life-saving programs and services. To become a member of the Legacy Society, the IMF requests that individuals simply confirm their planned gift in writing. No minimum commitment is necessary.

The Hope Society

The IMF's sustained giving program, The Hope Society, allows members to make recurring contributions on a monthly or quarterly basis. Hope Society participants make a large impact on the IMF's mission by making small, regular donations to the organization. Most Hope Society members ultimately donate more over the course of a year through this program than they would in a single lump-sum donation, for which the IMF is truly grateful. Since being launched in August 2009, The Hope Society has grown significantly to include 138 participants who donated \$17,500 during the 2009-10 Fiscal Year.

The Hope Society



*Cultivating the future
by planting the seeds
to sustain the IMF*



Steven Hirschorn
Overland Park, KS

When Steven Hirschorn was diagnosed with myeloma in August 2007, he was already aware of myeloma. He had first heard the word a mere two weeks before, when his friend was diagnosed.

Yes, he had *heard* of the word, but as Steve reflects, "I was totally unaware of what myeloma was." That friend recommended the IMF Hotline in order to get an understanding of the disease. "The Hotline was phenomenal in answering my questions," Steve says.

He continues to use the IMF to educate not only himself, but also to educate others – and to raise awareness about myeloma. To his family, friends, and neighbors, he passes along IMF-authored information booklets addressing myeloma disease and treatment. He has also distributed more than 200 of the IMF's myeloma awareness wristbands. As Steve sees it, education and awareness are two of the most powerful tools for advocacy.

Funding for myeloma research is the other tool Steve sees as vital to the cause. When he learned about the IMF's *Brian D. Novis Legacy Society*, Steve immediately knew that it was a simple and powerful way that he could make even more of a difference. By specifying now that he will be leaving a part of his estate to the IMF, Steve has the immediate satisfaction of knowing he's contributing to myeloma's future research and development.

"Myeloma is such a rare disease and does not get the funding for research that other cancers do," Steve says. "I want to make sure that I do what I feel is necessary to help others and be part of the cure."

"The IMF has been so good to my family and me. That's why I wanted to specify that my partnership in the cure be linked with the IMF and everything that they do."

Michael McKean Wins One Million Dollars for the IMF

On May 7, 2010, the world saw the IMF receive \$1,000,000 when Michael McKean won the *Jeopardy!* Million Dollar Celebrity Invitational. It is the single largest gift in the IMF's



20-year history, and is being used to establish the McKean-Grayson Education and Research Fund, in honor of Michael and in memory of his friend, Lee Grayson.

A Grammy Award winner, an Academy Award nominee, and a multi-talented actor, singer, writer, and director, Michael had never heard of myeloma when Lee was

diagnosed. "But throughout it all, Lee was working, he was staying vital," Michael recalls.

Michael's introduction to the IMF came from *Multiple Musicians Against Multiple Myeloma*, a fundraiser that Lee first produced with Naomi Margolin in 2002, several months before he passed away. Michael's appreciation of the IMF further solidified when Peter Boyle also passed away from

myeloma; if the IMF was important to Lee and Peter, it was important to him. In 2007, Michael raised over \$45,000 for the IMF by headlining *Concert For A Cause*.

As for *Celebrity Jeopardy!*: "David Letterman once called me smart on air," Michael says, as the explanation for his initial selection in 1999, as a standby. He subsequently made the show, and had already won \$25,000 for the IMF in 2006.

"Because of the money at stake, the material for this year's *Celebrity Invitational* was more difficult than our normal celebrity fare," says host Alex Trebek of the 2010 event. Michael won his quarterfinal round, then his semi-final round, then – eventually – found himself on the final day of the Finals.

During Final *Jeopardy!*, there was a technical glitch. Taping paused for five minutes before he could reveal his answer, and his wager. "It was this crazy time bubble," Michael says – because he did the math, and realized he'd won. For five whole minutes he had to keep it to himself.

Once the news was out, the IMF was flooded with messages from grateful patients all over the world. The IMF forwarded these thoughts to Michael, who sent this letter in response:

To All,

I just got back from New York City, where I had spent an unanticipated month playing the role of The Stage Manager in Thornton Wilder's *Our Town*. I had long admired this brilliant production now residing at the Barrow Street Theatre, and to wind up playing this great role for the month of June was breathtaking.

Do you know the play? It's only about everything in the world: all the mysteries of the universe reflected in this little dewdrop of a town, Grover's Corners. Performing the role put me at the center of that universe and I will miss the symmetry and beauty of Wilder's world.

Upon returning to Los Angeles, I opened a bulging envelope to discover a huge stack of printed emails, cards, and other communications from you: the diagnosed, the survivors, the brave ones, and your brave families. It took a while to read them all; I had to stop often to breathe, count my blessings, hug the kids... you know what I'm talking about here.

I'm a little overwhelmed by your gratitude. I took a little (mostly trivial) knowledge into a TV game show, did my best against some worthy opponents and emerged with a chunk of cash with IMF's address on it. Your thanks are much appreciated; your stories, shared via email, etc., are appreciated even more. I will treasure them always.

We all live in hope: here in California, in New York, in Grover's Corners, and wherever you may be, we're all hoping for a cure, a breakthrough, a miracle to offset the terror of this disease. Hope begets hope, and any move toward the realization of these hopes and prayers is a good move. I'm proud to have been of some help in this, and prouder still to be associated with all of you, with this great organization, and with this hopeful step into the future.

Yours,
Michael McKean

3rd Annual Comedy Celebration

“The IMF helps so many people in their fight, and it is amazing to see this superstar support.”

– MARY BURKE, Delavan, WI

On November 7, 2009, nearly 1,200 people packed the Wilshire Ebell Theatre in Los Angeles, CA for the IMF's 3rd Annual Comedy Celebration benefiting the Peter Boyle Memorial Fund. This annual event once again broke IMF fundraising records by bringing in \$650,000 for the organization's award-winning research program.



This year, Amy and Steve Weiss joined Loraine Boyle as event co-chairs. Together, they put on a show featuring a fantastic cast of celebrity comedians who agreed to come out in support of the IMF. The event, hosted by Ray Romano with the help of Jimmy Kimmel, featured appearances from Jason Alexander, Brad Garrett, Doris Roberts,

Bob Saget, Fred Willard, and a special musical performance by Tenacious D with Jack Black and Kyle Gass.

The IMF also welcomed VIP attendees to enjoy a pre-show cocktail party and silent auction, which made a significant impact on the overall success of the event. Items up for bid in the auction included guitars signed by Sting and Meat Loaf, boxing gloves from Muhammad Ali and Sugar



Ray Leonard, and a fantastic assortment of trips, memorabilia, and jewelry that were graciously donated for the cause. VIP guests were also treated to a post-show champagne and dessert reception that lasted well into the night.

Member Fundraisers

“I promised my husband we would turn the pain we experienced into something positive and meaningful. The IMF offered much encouragement and support as I organized my first fundraiser.”

– JOANNE GUNTHER, Aberdeen, MD

One of the IMF's longest running development programs, Member Fundraisers empower myeloma patients, their families, and their friends to generate support on a grassroots level, holding events in and around their communities to raise funds and awareness in support of the IMF. These member fundraisers generate critical funds for the fight against myeloma, increase awareness of the disease, and inspire patients, their families, and their friends to keep fighting. Some of the larger fundraisers are able to fund a Brian D. Novis Research Grant – a testament to the efforts of regular people with an extraordinary dedication to the IMF's mission.

From October 2009 through September 2010, IMF members held 55 events and raised over \$350,000. The IMF is tremendously grateful to this passionate and devoted group of members. Together, they make a profound impact on IMF programs, services, and research initiatives.



Lisa Mehalick
Treesdale, PA

Soon after her mother's myeloma diagnosis in 2005, Lisa came to see the IMF as a touchstone. “The IMF kindly shares with us a community that enhances our knowledge, understanding, and compassion,” Lisa says. “These are essential tools to navigate through this very complex disease.”

Despite a busy life, which now includes six children, Lisa felt compelled to support the IMF research that is now so critical to her entire family. In November 2007, she debuted *Jeans for Jewels* – the first fundraiser she ever spearheaded – creating a casual (jeans) yet elegant (jewels) evening of food, drink, and revelry. The results astounded her, not just in the dollars raised, but also in the abundance of people who donated their time, resources, and love.

In September 2010, Lisa hosted her second annual *Jeans for Jewels* event. It keeps growing. It is now so widely known that she will need to double the size of her venue next year. But in her heart, it remains the same. “It shows my mom my love for her, as well as sincere appreciation for all she has done and continues to bravely do.”

And although *Jeans for Jewels* started as a way to give back, Lisa now sees that she has created something even more profound for herself and her family. “Planning a fundraiser takes away the spectator position and gives us a strong sense of hope, and a little more control over a situation that at times can feel like the rug is being pulled out from under us,” she says.

She urges other IMF members to create their own fundraisers, despite their busy schedules, despite their fear or lack of experience. “The support of your friends, family, and even strangers will warm your heart in an unbelievable way.”



Miles For Myeloma 5K Walk/Run



Cabaret For A Cure



Timberwolves 5K Run/Walk for Research



RHS Open Golf Tournament

Member Fundraisers held between October 1, 2009 – September 30, 2010

Benefactors' Circle \$25,000 and up

Miles For Myeloma 5K Walk/Run
Philadelphia Multiple Myeloma
Networking Group,
Central New Jersey Support Group,
Northern New Jersey Support Group
Philadelphia, PA

Founders' Circle \$10,000 - \$24,000

**Carolyn Czerkies
Charity Golf Outing**
Czerkies Family
Naperville, IL

Coach Rob's Benefit Bash
Rob Bradford
Apopka, FL

J.C. Golf Tournament
David Johnson
St. Cloud, MN

Music Against Myeloma
Slava Rubin
New York, NY

WAMP Swim-A-Thon
Stafford Family
West Hartford, CT

Jeans & Jewels Gala
Lisa Mehalick
Gibsonia, PA

Fishing For A Cure
JoAnne Gunther
Aberdeen, MD

RHS Open
Steven Saletan
Mt. Pleasant, SC

Partners' Circle \$5,000 - \$9,999

**Heuer Memorial
Golf Tournament**
Nancy Heuer
Caledonia, NY

Pytlík Walk of Hope
Barb Pytlík
Tonawanda, NY

**Trooper Benson Klein
Research Fund**
Benson Klein
Bethesda, MD

Dennis Werra Fundraiser
Jayson Werra
New Berlin, WI

Divestco Norton Golf Tournament
Calgary, Alberta, Canada

Paparella Family Fundraiser
Carl Paparella
St. James, NY

Associates' Circle \$1,000 - \$4,999

Matthew Jacobs Annual Fundraiser
Matthew Jacobs
Frisco, TX

Bridge Blasts Myeloma
Ann Girod
Potomac, MD

**Meredith Fiacco
Memorial Golf Tournament**
Melanie Nicols and Suzanne Fiacco
Potsdam, NY

On The Fritz Fundraiser
Fritz Coleman
Studio City, CA

**Multiple Musicians
Against Multiple Myeloma**
Naomi Margolin
Great Neck, NY

**Multiple Colors
for Multiple Myeloma**
Pam Larsen
Honolulu, HI

Cabaret For A Cure
Courtney Charatsaris
Tonowa, NJ

**Margaret R. Cole
Memorial Fund**
Roger Cole
Upper Montclair, NJ

Timberwolves 5K
Julianne Basques
Groveland, CA

Twin Cities Fundraiser
Pat Harwood
St. Louis Park, MN

**Jack's 6th Annual
Texas Hold'em Benefit Bash**
Jack Aiello
San Jose, CA

Lucier Birthday Fundraiser
Lynn Lucier
San Juan Capistrano, CA

Who's Your Daddy? Rally
Lisa Cash
Paducah, KY

**Jerry Walton's Veterans
Against Myeloma Campaign**
Jerry Walton
Virginia Beach, VA

Marioni Salon Fundraiser
Kerri Marioni
Newark, DE

Our Friend Dan Fundraiser
Dan Odegard
St. Paul, MN

**Central Florida Support Group
Car Wash & Bake Sale**
Ken Fabian
Apopka, FL

TriBeCans Against Myeloma
Donna Marotta
New York, NY

**Chinatown Optical
Fundraiser**
Kaleena Ma
New York, NY

**Alexander MM
Fashion Show**
Nora Alexander
Louisberg, TN

Cirque De La Mode
Ashley Tarter
Temecula, CA

Passport To A Cure
Greg Strouse & Kim Simecek
Brighton, MD

**Celebration of Life
Singers' Fundraiser**
Garden Grove, CA

MMORE Foundation
Nancy Kaufmann
Columbus, OH

Friends' Circle \$500 - \$999

Bon-Ton Fundraiser
Suzanne Fiacco and Melanie Nichols
Potsdam, NY

Pifler's Car Show Fundraiser
Randy Cheney
Golden, CO

Ida's Day
Debbie Hadeka
Castleton, VT

**Christine Phillips
Fashion Show "The Bloom"**
Christine Phillips
Voorhees, NJ

**Paul Keddell's Veterans
Against Myeloma**
Paul Keddell
Poquoson, VA

Craft Fair Fundraiser
Carmen Scibetta
Port Washington, NY

Kindness For A Cure
Denise Bencel
Quakertown, PA

Under \$500

**Aslantrends
Knitting Challenge**
Angelo Fernandez
Port Washington, NY

Walk for Myeloma
Denise Vidot
Miami, FL

Burr Walk
Kelley Burr
San Diego, CA

**Bob Brunner's Veterans
Against Myeloma Campaign**
Bob Brunner
Virginia Beach, VA

Hirschorn For Myeloma
Steve Hirschorn
Overland Park, KS

Stokes Art Fundraiser
Bill Stokes
Roanoke, VA

**The Cosmopolitans
Fundraiser**
Arlington, VA

Hanson Cards
Jeffrey O. Hanson
Overland Park, KS

Help from Heaven
Meghan Lowell
Rollingstone, MN

FINANCIAL STATEMENT

INTERNATIONAL MYELOMA FOUNDATION Statement of Financial Position September 30, 2010

Assets

CURRENT ASSETS

Cash and cash equivalents	\$1,694,124
Contributions and other receivables	738,270
Prepaid expenses	384,919

Total Current Assets	\$2,817,313
-----------------------------	--------------------

PROPERTY AND EQUIPMENT, at cost

Furniture, fixtures and equipment	58,354
Computer equipment	175,478
Computer software	667,688
Laboratory research equipment	449,200

1,350,720

Less accumulated appreciation	(825,566)
-------------------------------	-----------

Net Property And Equipment	\$525,154
-----------------------------------	------------------

TOTAL ASSETS	\$3,342,467
---------------------	--------------------

Liabilities & Net Assets

CURRENT LIABILITIES

Accounts payable and accrued expenses	\$379,746
Deferred and unrestricted educational grants	1,987,279
Current obligations under capital leases	1,619
Line of credit	25,000

Total Current Liabilities	\$2,393,644
----------------------------------	--------------------

OBLIGATIONS UNDER CAPITAL LEASES, less current portion	6,170
---	--------------

NET ASSETS

Unrestricted	942,653
Temporarily restricted	-

Total Net Assets	\$942,653
-------------------------	------------------

TOTAL LIABILITIES AND NET ASSETS	\$3,342,467
---	--------------------


For a copy of our complete audited financial statements, please contact the IMF office

INTERNATIONAL MYELOMA FOUNDATION

Statement of Activities

For the Year Ended September 30, 2010

Revenue Breakdown



Change in Unrestricted Net Assets

REVENUES

Educational grants	\$5,689,636
General contributions	2,263,175
Fundraising event income	56,568
Seminar fees and support group income	61,847
Donated services	182,150
Interest income	8,315

Total Revenues

\$8,261,691

Net Assets Released From Restrictions

Satisfaction of program restrictions	\$442,095
--------------------------------------	-----------

Total Unrestricted Revenue And Other Support \$8,703,786

Expenses

Program expenses	6,734,128
General supporting expenses	496,349
Fundraising expenses	512,943

Total Expenses \$7,743,420

INCREASE IN UNRESTRICTED NET ASSETS 960,366

Changes in Temporarily Restricted Net Assets

Contributions	145,990
Fundraising event, net of direct benefit to donors of \$367,946	296,105
Net assets released from restrictions	(442,095)

Increase in Temporarily Restricted Net Assets

-

Increase in Net Assets

960,366

NET ASSETS (DEFICIT), September 30, 2009

(17,713)

NET ASSETS, September 30, 2010


\$942,653

For a copy of our complete audited financial statement, please contact the IMF office

INTERNATIONAL MYELOMA FOUNDATION

Statement of Functional Expenses

For the Year Ended September 30, 2010



Total Program Expenses	6,734,128
General Supporting Expenses	496,349
Fundraising Expenses	512,943


Total Expenses	\$7,743,420
-----------------------	--------------------

Breakdown of Expenses by Program

PROGRAM	TOTAL EXPENSES
Patient & Family Seminars	1,123,439
Research	999,914
Education & Awareness	701,461
International	623,670
Support Groups	569,206
Nurse	544,830
Clinical Meetings	463,384
Advocacy	395,671
Hotline	345,862
Website	225,198
Bank On A Cure®	219,079
Myeloma Today	213,785
Information Mailings	148,305
Public Relations	107,275
Myeloma Manager	53,049

Total Program Expenses	\$6,734,128
-------------------------------	--------------------

For a copy of our complete audited financial statement, please contact the IMF office



HONOR ROLL

The International Myeloma Foundation gratefully acknowledges the many people and organizations which have made contributions to our various programs and projects during the past year. Without them, the IMF would not be able to continue providing the excellent, high-quality programs and services upon which our members have come to rely. Their generosity allows the IMF to:

- Convene the Inaugural International Myeloma Working Group Summit bringing together the world's foremost experts to collaborate on the future of myeloma research world-wide;
- Develop and maintain its highly-acclaimed website performing daily updates of the most relevant information available and made available 24 hours a day to all those interested in myeloma;
- Advocate on behalf of the entire myeloma community to ensure that myeloma research and patient care issues are ever-present in our lawmakers' thoughts;
- Invest wisely in research programs like the International Myeloma Working Group and Bank On A Cure® that lead to better treatments for patients today while also funding research grants that lead to critical breakthroughs for tomorrow;
- Maintain the Hotline and ensure that its coordinators are up-to-date on the latest research and treatment options so that patients, family, and friends always have a place to turn;
- Expand successful programs such as the Regional Community Workshops to reach even more patients and families, while maintaining unwavering support of established and relied upon programs like the Patient & Family Seminars;
- Continue to produce and regularly update the more than 100 publications that support patients, doctors, and nurses in making informed treatment choices.

The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.

The IMF is here for you.

Chairman's Circle \$100,000 and above

AMGEN Oncology
The Binding Site, Ltd.
Celgene Corporation
Medtronic, Inc.
Merck & Co.
Millennium: The Takeda Oncology Company
Onyx Pharmaceuticals, Inc.
Quadra Productions / Jeopardy!

President's Circle \$50,000 - \$99,999

The Virginia and Leonard Marx Foundation / Jennifer and Bud Gruenberg
Novartis Pharmaceuticals
Dorothy and John O'Dwyer
Philadelphia Multiple Myeloma Networking Group
Alice and Louis Weiss
Michael Windsor

Benefactor's Circle \$25,000 - \$49,999

Patricia and Bruce Bartlett
CBS Corporation
Susie Novis and Dr. Brian Durie
Robert C. Ebersole
Genzyme Corporation
John J. McDonnell & Margaret T. O'Brien Foundation
Jae-Hoon Lee, MD
Ortho-McNeil Pharmaceutical / Johnson & Johnson

Founders' Circle \$10,000 - \$24,999

Henry Belber
Cancer Cure of America
Coach Rob's Benefit Bash, Inc. / Kimberly and Robert Bradford
David Geffen Foundation
Donna and Steve Feig
GfK Research Matters AG
Cindy and James Gilbert
Dianne M. Glick
HBO Inc.
J.C. Invitational Golf Tournament / Beverly Lundorff
Joy and Bill McGinnis
Estate of Caroline McWilliams
Alex Meneses and John Simpson
Paramount Network Television

Monica and Philip Rosenthal
Sebia, Inc.
Louise Takata
The Estate of Janet Kreh
The Hazel R. Osborn Charitable Remainder Unitrust
Dorothy* and Hollis Tinsler
Twentieth Century Fox
Phyllis and Allan Weinstein
Worldwide Pants, Inc.

Partner's Circle \$5,000 - \$9,999

Stacey Annen
Aptium Oncology, Inc.
Susan and Frank Armo
Loraine Boyle
Brillstein Entertainment Partners
Bristol-Myers Squibb Company
Cephalon, Inc.
Clifford and LaVonne Graese Foundation
Creative Artists Agency
Diplomat Specialty Pharmacy
Disney/ABC
Divestco Inc.
Estate of Susan Q. Pinals
Joele Frank and Larry Klurfeld
Genentech, Inc.
David Girard
Giving Generations Foundation
Helene S. Whitman Memorial Cancer Fund / Joel Whitman
Charlotte and Dale Herbrandson
InSightec
Janssen-Cilag
Susan and Michael Katz
Kenneth A. Abrams Charitable Foundation
Mrs. C. S. Ledley
Lindsay Luke
Charlene and Carl Paparella
Patheon Pharmaceuticals, Inc.
Joy and Ronald Paul
Rose and Sherle Wagner Foundation / Amy Wagner
Janet and Marvin Rosen
Carol Ann and Paul A. Rothman
Marty Singer / Lavley & Singer, CP
Spencer Howard Signature Events
Twin Cities Myeloma Foundation
Chuck Ver Burg
Jean Viglas
William Morris Endeavor Entertainment

Associate's Circle \$1,000 - \$4,999

Nora Alexander
Mark Alles
Altitude Aviation Inc
Jennifer and Bryan Anderson
Monica and Kristofer Anderson
Linn Anderson
Sandra Andrews
Jennet Walker and John Auerbacher
Marty Barrett
Bill Barretta
Beatrice Bass
Suzanne Battaglia
Barbara Baumstein
Gary Benanav
Lisa Bernstein
Mr. and Mrs. Jake Bloom
Richard Boisture
Louis Borick
Harriet Rosetto and Rabbi Mark Borovitz
Noeline and Dr. Henri Boshoff
Paula Boultsbee
Sandra Powers and Bradford Porter
Mitzi and Gerald Bozarth
Warren Breslow
Wendy Breslow
L.J. Brewer
Carrie Brillstein
Henry Brock
Prudy and David Brown
Mari and Ward Bukofsky
Alan Bundy
Jenya and Mark Buntzman
Robin Green and Mitchell Burgess
Colleen and John Busch
Carter Foundation, Inc
Jack Carter
Tom Carver
Celebration of Life Singers
Celgene Germany
Celgene International
Manish Chablani
Charlotte and William Hinson Charitable Foundation
Rose Chen
Chinatown Optical Inc.
Karen Chopra
Louise and Frank Chut
Citigroup Asset Management

Bill Clifford
 Coalition of Cancer
 Cooperative Groups
 Gail-Ann Colaruotolo
 Joseph F. Coleman
 Janice Corwin
 Courteney Cox
 Marilyn and Lee Cox
 Barbara and James Coy
 D&B Trucking
 Betsy and Paul Dawes
 Aldo Del Cox
 Design Printing
 Catherine Blaney
 Gordon Doble
 Christina Dodd
 Marjatta* and Niall S. Doherty
 Dr. Armand Dorian
 Jane Drexler
 Alice Duffy
 John Dunn
 Debbie and John Dyer
 Clarice L. Eder
 Joseph Daniel Ellis
 Evening 4 a Cure / Ashley Barit
 Frances Fahsel
 Kate and Douglas Farrell
 Stephanie Hope Feld
 Mark Filip
 Deborah Fine-Schneider and
 Martin Schneider
 David Fink
 Danny Fishman
 Fox Broadcasting Company
 Barbara and Buddy Freitag
 Sid Fry
 Susan and Daniel Gannon
 Berta and Frank Gehry
 Barbara and Jack Geiger
 Francoise Gerard and
 Andree Couteele
 Bob Gersh
 Judith and George Goldman
 Goldman, Sachs & Co.
 Matching Gift Program
 Nancy and Gary Goodenough
 Corey P. Graney*
 Susan and Richard Grausman
 Edna Gray
 Wendy Barish and Michael Greenstein
 Erwin Gudelsky
 Virginia E. Gunderson

Gursey | Schneider LLP
 Sue and Alan Haber
 Dr. John Hagopian
 Anne R. Hearst
 Jason P. Hendler and Chad Billmyer
 Diana and George Holway
 Terry M. Hopkins
 Ivory Investment Management
 Mike Jackson
 Brenda and Bart Jacobs
 Margaret and Ralph Jensen
 Sarah Jessup
 John & Hilda Arnold Foundation
 Irene and Edward Kaplan
 Arnold Kas
 Retha Keenan
 T.F. and I.W. Kelly
 Nancy Kelsey
 Deborah Kennedy
 Esther and Bernard Klein
 Carol and Benson Klein
 Roberta and Raymond Klein
 John Krehbiel
 Amy Bard and Stuart Kuritsky
 Laurie and Andrew Kuzneski
 Charlene and Dr. Robert Kyle
 Kay and Ernest Lambert
 Jeffrey Lassinger
 Andy Lebkuecher
 Pamela and Lawrence Leigh
 Lucy Simon and Dr. David Levine
 Kathleen and Charles Lewis
 Katherine and Carl Locher
 Randi Lundy
 Jeff Lynne
 Mary and Ken Makowka
 George Malouly
 Joann K. Malta
 Joe Manganiello
 Multiple Musicians Against Multiple
 Myeloma / Naomi Margolin
 Michael Marks
 Sylvia and Richard Mase
 Maurice and Carol Feinberg
 Family Foundaiton, Inc.
 Randi Max and Stephen Holloway
 Amy Mazur Liberman
 Patty and Fred McClintock
 James E. McDonald
 Michael McLemore
 Geoff Meacham

Mechanical Technologies Group
 Randy Mehrberg
 Rose Linda Meltzer
 Meredith Fiocco Memorial
 Golf Tournament
 Microsoft Giving Campaign
 Judith E. Miller
 Susan Molineaux
 Montclair Beach Lub, Inc.
 Ellen Moore
 Kathleen Moore
 Leigh Morris
 Multiple Myeloma Opportunities
 for Research and Education
 Ardie S. Myers
 Jerome F. Mytych
 NBC Entertainment
 Sharon and Chuck Newman
 Agnes Nixon
 Paradigm
 Barbara and Channing Parrett
 Mark Peltz
 Pepsico Foundation
 Sandy and Steve Perlinder
 Pfizer Foundation
 Matching Gifts Program
 Craig Pilgian
 Pincus Family Foundation /
 Leslie Pincus
 Joyce Sullivan-Posladek and
 William Posladek*
 Queensboro Elks Lodge 878
 Recellular, Inc.
 Lawrence Reynolds
 Robert Rice
 Judith and Milton Riseman
 Cindy and Leon Rittenberg, Jr.
 Pat and Jim Robertson
 Laurie K. Robinson
 Sylvana and Matthew Robinson
 Rocky Mountain Medical Imaging, P.C.
 Linda and Arthur Rodbell
 Jane Rose
 Sandy and Mark Rothman
 Marilyn and Gerald Royce
 Suzanne Saletan
 Salon 926 LLC
 Rosella and Dr. Barry Samson
 Robert Santos
 Susan Sarandon
 Laura Schneider
 Laura and Timothy Schneider

Paul Schumacher
 Schwab Fund for Charitable Giving
 ScienceFirst, LLC
 Carrie* and David Sears
 Semitropic Water Storage District
 Tib Shaw and Dan Odegard
 Siemens Caring Hands Foundation
 Mary Anne Siska
 Keith Small
 Sarah and Melvin Small
 Ursula and William Smeader
 Daphne Smith
 Iris and Michael Smith
 Stephen Smith
 Susan and Philip Smith
 David F. Spalding
 George Speen
 Marion State
 Phyllis and Richard Stern
 Michael Stone
 Elaine* and Thomas Stone
 Stroh Family Foundation
 Dory and Alex Szeles
 The Bank of Castile
 The Estate of Carol Axelrod
 Luke Thompson
 Marilyn Thompson*
 Catherine Trizzino
 United Talent Agency
 Delores Van Wyck
 Dr. David Vesole
 Sandy Hill and Frank Walsh
 Joe Walsh
 Lindsay and Jerry Walton
 Patricia and Clark Ward
 Barbara Warren
 Steve Weiss
 Ann T. Welles
 Holly and Jayson Werra
 Jan Williams
 Marilyn Wilson
 Michael Winkler
 Carol Holmes Wolf
 Sharyne and Mitchel Wolfe
 Beth and Woodring Wright
 Carolyn and Gary Youngberg
 Jill and Bobby Zarin
 Kathryn and Martin Zenthoefer
 Judy-Ann Zoghby
 Michele and Arnold Zousmer

Friend's Circle **\$500 - \$999**

Kevin and James Abernathy
 Pamela Ahlen
 Nelleke and Jack Aiello
 Mary Ann and Jeffrey Allyn
 Joanne and Robert Alspaugh
 Susan L. Anabo
 Apex Industrial Automation LLC
 Rosemarie Aramanda
 AT&T Services, Inc.
 Lauren and George Baker
 Madelyn and Kamel Baladi
 Pauline and Kenneth Barclay
 Barnes Group Foundation, Inc.
 Richard Barofick
 Maggie and Steven Bass
 Nancy Baxter and Bob Stone
 Sandra S. Bazley
 Susan and David Beck
 Marion and Henry* Becker
 Malea and Michael B. Bell
 Molly Gomoll and Michael Benjamin
 Marcy Bernstein
 Dr. Brian Berryman
 Carl Beverly
 Joan Biddison
 Barbara and Dr. Thomas Blackburn
 Doris and Arnold Bodmer
 Marlene and Loren* Bruch
 Elizabeth Burgett
 Campbell Soup Foundation
 Denise Carmody
 Cars 4 Causes
 Janice and John Cartwright
 Christopher Chandlee
 Beatrice Chaney
 Georgann and Ron Charlton
 Kimberly and Randy Cheney
 Michael Chernuchin
 Chesapeake Branded Packaging
 David Cianfrini
 Clinic Properties
 Kitty and Byron Collier
 Ronald G. Collman
 Commonwealth Home Health, Inc.
 Community Foundation
 for Greater Atlanta
 Content Partners
 Tim Curdo
 Athena and George Curley

...There is the IMF



INTERNATIONAL MYELOMA FOUNDATION

12650 Riverside Drive, Suite 206

North Hollywood, CA 91607 USA

800-452-CURE

TheIMF@myeloma.org

myeloma.org

FOR
2020

D.J. Electric	Grace Gunnlaugsson	Christopher Lisy	Dawn Randall	Soren Thorvald
Janet and Robert Daily	Bonnie and Alan Hammerschlag	John Lively	Laura Ratner	Gordon Tichell
Frances Daley	Joyce and Jack Harper	Scott Longfield	Eugene Razzetti	Debbie and Albert Tone
Blythe Danner Paltrow	Dede Harris	Longmont United Hospital	Cynthia Reich	Judith Richmon Torrez and William Jewell
Penelope Dawkins	Kenneth Harris	Katy Lough	Michael Reinert	Shigeko and Joseph Trudeau
Brigitte Demes	Judith Hartig-Osanka	Randi and Anthony R. Lovett	Anne Reuther	Trust Credit
Dennis A. Quinn & Associates	Betty and Steve Herman	Lauren and Brad Lundy	Hadley and Lee Rierson	Giann Tsai
Beth DeWoody	Rose Anne Herrmann	Reid MacDonald	Agnes and Larry Roberts	Eve and Jeffrey Tucker
Ann Dieperink	Michael Ewing Hill	Daniel Mangold	Anonymous	Rita Ullman
Kathryn Divine and Gary Swift	William H. Hodges	Brian Mann	Dr. Barbara Rodgers	Benita and Ronald Unger
Michelle M. Dowling	Cheryl and Doran Hougham	Darline Mappin	Mark Rolfe	United Way of DEAP
Nancy and Mark Duber	Craig Howard	Judy and William Matevich	Robert Rome	United Way of Greater Twin Cities
East Texas Support Group	Elsie Hull	Joseph Mattana	Harold Rosenson	United Way of the National Capital Area
Erica Hanson and Joshua Elbaum	IBM Corporation	Richard Mayo	Phillis Rosenthal	University of Medicine & Dentistry of New Jersey
Barbara and David Elson	Independent Charities of America	Sharon and Dennis McCarthy	Mildred Rowan	Jim Valley
Larry David Eudene	Marjorie and Almon Ward Ives	Margaret and Dennis McClure	Jane and Charles Rubey	George Ward
Ken Fabian	Gary Jacobs	Paul McKee III	Kim and Dr. Marty Rubin	Judy and Gerald Webb
Ursula Fairbairn	Danny Jacobson	Nancy and Christopher Meier	Jaen Sackett	Joyce and Wells Fenton
Adele and Mark Feldstein	Joan and John Jakobson	Janis Mekaelian	Stacy Samet	Dale White
Findley Bus Service, Inc.	Kathleen and David Johnson	Alan Melcher	Virginia Santikam	Todd White
First Exteriors LLC	Judith Johnson	Toby and Scott Melnick	Sandra and Richard Schutt	William Wiatrowski
Melissa L. Fisher	Nan Johnson	Cheryl Mercier	Diane and Jarvis* Seccombe	Sam Wissa
William P. Fisher	Kane Construction	Lorraine and Joseph Merluzzi	Carol and Truman Sechrist	Caroline and Herbert Wolf
Floyd, Skeren & Kelly, LLP	Boris Karpman	Midland States Bank	John J. Sengle	Alfre Woodard and Spencer Roderick
Tom Fontana	Kyoko Kashiwagi and Ronald C. Fischer	Cheryl and James Miller	Anne T. Shafer	David L. York
Jeanne and Robert Fowler	Martha Katz	Luvisminda Milo	Rosemary A. Shea	Dennis Zerr
Jan and Don Froeschle	Paul Katz	Natilee* and Kenneth Mintz	Christine M. Simpson	
Carolyn and Joel Fromer	Frances Kazan	Sgt Michael Mobley	Rachel S. Small	
Amy and Robert Gallo II	Kendall County Motors	Elena Moneti	Smart Wire LLC	
Judie and Howard Ganek	Mary and William Kenney	Richard Moniz	Janet Soltau	
Judith and Martin Gang	Joan and John Knapton	Lawrence Montgomery	Linda and John Spanier	
Gail L. McNabb and E. H. Gardner	Tracy Kolker	Lori and Cliff Morden	Martha and Olvis Spencer	
Sandra Gary	Kathleen and Dr. Edgar Koschmann	Donna and Derald* Nantkes	Leonard Splane	
Irene and Laurence Gauthier	Spencer Krane	Nancy Nashban	Diane and Steven Staves	
Catherine and Thomas Gayle	Gwen Kraxberger	Michelle and Gregory Nathan	Robyn Stecher	
Marilyn and Dr. Gerald Gelfand	Elizabeth and Grzegorz Kurantowicz	Margaret and Daniel Nencka	Stephens-Marquis Associates, Inc.	
Stephen Gendel	Richard LaGravenese	Network for Good	Sandra Stern	
Samantha Gerber and Eric Levine	Elaine and Dale LaLonde	Sally and Carl Neu	Valerie and Mike Stevenson	
Paul Giancola	Jamie Larsen	Jean and Al Nickerson	Riza Stillwell	
Patricia and Robert Gibb	Laurie Lasseter	Nine-Tee-Niners	Heather Stoeffler	
Martha Gibbs	Mai Le	Northeast Utilities	Enid Stone	
Robbe and Thomas Gilbo	Carol Le Roy	Joan O'Callaghan	Anonymous	
Arlene and Ed Gillis	Keith B. Leffler	David Offensend	Virginia and Thomas Swann	
Michele and Michael Ginsburg	Linda S. Leffler	Mary Olsovsky	Maurry Tamarkin	
Gary Gittelsohn	Dr. Stuart Lerner	PayPal	Mindy and Randy Tammara	
Fred Glantz	Adrienne and Martin Levine	Marnette and Paul Perry	Joel Tan	
Leanne and Bradley Glassman	Robert Levine	Joe A. Petrozziello	Kim and Eric Tannenbaum	
Jane Godin	Ross Levinsohn	Karl Pettijohn	The Gavel Group, Inc.	
Ronda Gomez-Quinones	Nancy and Larry Levitt	Beki Picus	The Greater Kansas City Community Foundation	
Carl Gottlieb	Joan and Evan Lewis	John Pladziewicz	The Learning Shop	
Patricia Gradillas	Elizabeth and Patrick Lezark	Jody Pokorski	The Mark Kingseed and Joan Breitenbucher Foundation	
David Gresens	Barbara and Robert Liberman	Quality Mechanical Systems, Inc.	Hockadoo Company L.P.	
Margaret and Patrick Grippe	Sam Liebovich	Barbara and Mark Rabin		
Deborah and Allen Grubman		Patricia and Jeffrey Raikes		

The IMF's 2010 fiscal year ran October 1, 2009 – September 30, 2010. This list includes gifts received between those dates. We apologize for any omissions or errors. Please call the IMF office to report any corrections needed.

Every gift is appreciated by the IMF. Every dollar counts. Nearly 5,000 people contributed gifts between \$1 and \$499, totaling \$506,940 of support from programs, services and research. Unfortunately, space does not allow for everyone's name to be listed but every donor is deeply valued.

* deceased

Until there is a cure... There is the IMF.

**INTERNATIONAL
MYELOMA
FOUNDATION**



myeloma.org